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ABSTRACT 
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant 
and non-malignant disorders. However, transplantation related morbidity and mortality limit its 
use.  The complications of the HSCT procedure can be caused by several factors including 
toxicity of the conditioning regimen and allogeneicity. Despite the fact that 50% of the 
transplanted patients are conditioned with chemotherapy, the majority of transplantation models 
are based on radiation. In the present thesis, we utilized a HSCT mouse model following 
conditioning using busulfan-cyclophosphamide (Bu-Cy) to explore mechanisms and factors 
that might affect graft versus host disease (GVHD) and/or treatment related toxicity, thus 
altering transplantation outcome.    
Study I:  Was designed to investigate early cell dynamics during the development of GVHD 
after allogeneic HSCT. We found an early expansion and activation of dendritic cells (DCs) 
that peaked by day +3 post HSCT. The T cell expansion started later and reached its peak by 
day +5 post HSCT. The majority of these cells were donor CD8+ cells. The inflammatory 
cytokines (IL-2, INF-γ and TNF-α) also reached maximum levels by day +5. The results 
showed the important role of donor DCs in GVHD.    
Study II: We studied the early histopathological changes in several organs at different time 
points from conditioning, as well as during the development of GVHD, until day +21. The 
study showed that the liver and spleen were the most affected organs; however, no 
morphological effects were detected in the pancreas, heart, lungs or kidneys after the 
conditioning regimen. Histopathological changes such as vasculitis, inflammation and apoptotic 
cell forms in the liver, spleen, pancreas, lungs and heart were observed during GVHD 
development, however, only hypocellular spleen and extramedullar hematopoiesis were 
detected in syngeneically transplanted animals. No morphological changes were observed in the 
kidneys in either HSCT setting. These results may help in understanding mechanisms 
underlying the development of GVHD.     
Study III: We investigated the toxicity of Bu-Cy conditioning regimen on the arteries. We 
found that the conditioning regimen enhanced acetylcholine relaxation in the mesenteric 
arteries through the increased expression of endothelial nitric oxide. In contrast, the sensitivity 
of the aorta to the acetylcholine was similar between the Bu-Cy treated group and the controls. 
However, the aortas from the treated animals had a higher sensitivity to noradrenalin. The Bu-
Cy treated animals had lower blood pressure, lower hematocrit and more endothelial damage 
compared to the controls. These results might help in developing prophylactic treatment for 
cardiovascular complications. 
Study IV: We studied the effect of omega-3 on the Bu-Cy conditioning regimen and on the 
allogeneic HSCT outcome focusing on GVHD. We used corn oil and standard food as controls. 
The mice that were fed omega-3 food had the lowest survival rate and showed early signs of 
GVHD. Omega-3 enhanced the effect of the conditioning regimen by increasing its 
myeloablative properties, decreasing the expression of CD4+CD25+FoxP3+ T cells and 
reducing their function. Less GVHD and a higher rejection rate were observed in the corn oil 
group. The higher death rates in the omega-3 fed group might be explained by a greater 
myeloablative effect and increased severity of acute GVHD. 
 
Taken together, these studies increase our knowledge of GVHD and conditioning related 
toxicity. This may improve treatment strategies and hence the clinical outcome of HSCT.  
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LIST OF ABBREVIATIONS 
 
AA Arachidonic acid 
aGVHD Acute graft versus host disease 
ALA Αlpha (α) – linolenic acid 
ALL Acute lymphoplastic leukemia 
APC Antigen presenting cell 
AT Active tension  
BM Bone marrow 
Bu Busulfan 
Bu-Cy Busulfan-cyclophosphamide  
Ca0PSS Calcium free physiological salt solution 
cAMP Cyclic adenosine monophosphate 
CaPSS Physiological salt solution  with calcium 
CB Cord blood 
cGMP Cyclic guanosine monophosphate 
cGVHD Chronic graft versus host disease 
CHF Cardiac heart failure 
COX Cyclooxygenase 
Cy Cyclophosphamide 
CyA Cyclosporine A 
DC Dendritic cell 
DHA Docosahexaenoic acid 
DSF Disease free survival 
EDTA Ethylenediaminetetraacetic acid 
eNOS Endothelial nitric oxide synthase  
EPA Eicosapentaenoic acid 
FBS Fetal calf serum 
FOXP3 Forkhead box P3 
G-CSF Granulocyte colony-stimulating factor 
GLA Gamma (γ) – linolenic acid 
GVHD Graft versus host disease 
GVL Graft versus leukemia  
HLA Human leukocyte antigens 
HSCT Hematopoietic stem cell transplantation 
HVG Host versus graft 
ICAM-1 Intercellular adhesion molecule 1 
ICopt Optimal internal circumference  
ICref Reference slack internal circumference  
INF-γ Interferon gamma 
iNOS Inducible nitric oxide synthase 
iPC Induced pluripotent stem cell 
KPSS Physiological salt solution  with potassium  
LA Linoleic acid 
LPS Lipopolysacharide  
LTB4 Leukotriene B4 
 
  
M.A. Microarteries  
MHC Major histocompatibility complex 
MSC Mesenchymal stem cell 
NK Natural killer cell 
NKT Natural killer T cell 
nNOS Neuronal nitric oxide synthase 
NO Nitric oxide 
PB Peripheral blood 
PBS Phosphate buffer saline 
PD-1 Programmed death-1 
PGD2 Prostaglandin D2 
PGE-2 Prostaglandin E-2 
PPARγ Peroxisome proliferator activated receptor γ 
PT Passive tension 
PUFA Polyunsaturated fatty acid 
RBC Red blood cell 
RIC Reduced intensity conditioning 
SCT Stem cell transplantation 
SNP Sodium nitroprusside 
SOS Sinusoidal obstruction disease 
TEM Transmission electron microscopy 
TNF-α Tumor necrosis factor alpha 
Treg Regulatory T cell 
TRM Transplant related mortality  
VCAM-1 Vascular cell adhesion molecule 1 
VOD Venoocclusive disease  
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Figure 1: 1950s – 60s history of stem cell transplantation 
 
 
1 INTRODUCTION 
1.1 HEMATOPOIETIC STEM CELL TRANSPLANTATION 
1.1.1 History 
The use of the atomic bomb in World War II was the beginning of understanding 
radiation and cell biology and subsequently the discovery of hematopoietic stem cell 
transplantation (HSCT) [1-2]. After lethal radiation dose, E. Donnall Thomas in 1957 
[3] was able to rescue the mice by infusing stem cells. HSCT was originally used as the 
last choice of treatment for malignancies. Since then, the application of stem cell 
transplantation has increased to cover a wide range of diseases including genetic and 
metabolic disorders, hematological malignancies and solid tumors. However, the 
progress from the experimental treatment to clinical practice was dependent on the 
development of several areas such as the histocompatibility system, drug development 
and mechanisms underlying different diseases [4-6]. The following diagram (Figure 1) 
illustrates the development of hematopoietic stem cell transplantation in 1950s and 
1960s [7].   
 
 
 
 
1.1.2 Indication  
The use of HSCT is continuously expanding to cover a broader range of diseases [8]. 
The diseases treated with HSCT are either acquired diseases or inherited disorders [9-
11]. Acute and chronic leukemia, multiple myeloma and lymphomas are among the 
most common hematological malignancies indicated for HSCT. While, Hurler, Hunter, 
Goucher, SCID, thalassemia and aplastic anemia belong to the most common non 
malignant disorders that are indicated for HSCT.    
 
1.1.3 Stem cell biology and cell therapy 
Following the success of HSCT, stem cell therapy has become a new promising 
approach for the treatment of several disorders. Today, stem cell therapy has entered  
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Figure 2: Stem cell plasticity 
clinical trials for tissue repair and 
other clinical applications. 
Mesenchymal stem cells (MSC), 
for example, are used in clinical 
trials for the treatment of cartilage 
damage, cancer, diabetes, 
neurodegenerative diseases [12-
13], tissue toxicity and graft versus 
host disease (GVHD) [14-16]. 
Neural stem cells are also used in 
phase I and II trials for several 
diseases including chronic spinal 
cord injury, advanced Parkinson 
disease and stroke [17-19], 
however, several challenges such 
as adequate cell survival in the 
recipient and proliferation have to be solved. There are several types of stem cells 
depending on source, function or developmental stage. Germ cells have the ability to 
develop into all body cell types and they are called totipotent cells [20-21]. Embryonic 
stem cells are pluripotent [22] and they have the ability to produce different types of 
cells and tissues. Somatic or adult stem cells are more tissue specialized cells. Adult 
stem cells have been identified in different tissues such as brain, bone marrow, 
peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian 
epithelium and testis. These cells reside in a special place called a stem cell niche. Stem 
cells remain quiescent and leave the niche when there is a requirement from the body 
due to any type of stress. Neural stem cells, hematopoietic stem cells and fat stem cells 
are all examples of more specialized types of stem cells. Although these stem cells are 
tissue specific, there is enough evidence to conclude that these stem cells have trans-
differentiation potential. Hematopoietic stem cells, for example, can be trans-
differentiated into hepatocytes [23].  
 
Natural trans-differentiations or reprogramming is a promising strategy in cell therapy 
for different kinds of injuries and diseases. Although embryonic stem cells have a 
higher capacity than adult stem cells to produce other tissues, their use is limited due to 
ethical and technical problems. Research continues to challenge and mimic the stem 
cell properties in vitro to achieve better treatment. Induced pluripotent stem cells 
(iPSCs) are in vitro modified stem cells with similar properties to mouse and human 
embryonic stem cells [24]. The therapeutic window for these cells is wide, as they have 
the potential to regenerate different tissues and thus to be used for the treatment of 
different types of diseases [25-28]. Somatic or adult stem cells also attract attention in 
scientific research, and due to their potential for so far incurable diseases. All types of 
stem cells have common properties in that they are capable of renewing themselves and 
supplying needs of the body whenever required. Stem cell self renewal is divided into 
long- and short-term self renewal. Long-term stem cells are not specialized, and they 
have the capacity to self renewal for an extended period of time, this feature is lost 
during specialization. The other common feature is that stem cells can differentiate to 
produce specific tissues. Better understanding of stem cell biology would improve the 
therapeutic approaches in regenerative medicine and in the treatment of cancer and 
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many other diseases. Figure 2 illustrates the plasticity of adult stem cells [29] and 
Figure 3 illustrates stem cell division and differentiation into different cell lineages 
[30].  
 
 
 
 
 
 
1.1.4 MHC system 
Histocompatibility matching is one of the factors that play a major role in 
transplantation outcome [6]. There is a large cluster of genes defined as a major 
histocompatibility complex (MHC) and has a high degree of polymorphism. This 
cluster of genes plays very important role in transplantation, immunity, inflammation, 
infection and different diseases [31-32].The complex region is divided conventionally 
into three classes; class I, II and III, each containing a cluster of genes with related 
functions.  Class I proteins are found on all body nucleated cells and present 
endogenous antigens that are processed by the proteasome to the cytotoxic CD8+ T 
cells. The exogenous antigens taken up by endocytosis or phagocytosis are degraded 
and loaded onto MHC class II, which are found in the immune cells such as B cells, 
dendritic cells and endothelial cells, then presented to helper CD4+ T cells. Class III 
genes encode the components of the complement system that target foreign cells and 
break their membranes. In humans, the MHC system is called a human leukocyte 
antigen (HLA) system and is located on the short arm of chromosome 6. It spans over 
four million base pairs of DNA and contains over 128 functional genes. The MHC 
Figure 3: Stem cell hierarchy  
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Figure 4: A represent human MHC and B represent mouse MHC 
complex in the mouse is known as H2, and is located on chromosome 17. Class I 
encodes the K, D and L and class II encodes the Ia (I-A and I-E) antigens [33]. BALB/c 
mice express the d haplotype whereas C57Bl/6 express the b haplotype in their gene 
products [34]. Figure 4 A & B represent human and mouse MHC, respectively.  
Due to the limited number of suitable donors and the risk of developing graft versus 
host disease (GVHD), MHC compatibility is still one major barrier to the success of 
HSCT. Consequently, there is extensive research to overcome this barrier; one 
approach is in vitro expansion of stem cells aiming to increase the number of cells, 
especially in cord blood transplantation [35]. Another aim is to produce cells that have 
less immunogenicity in order to overcome GVHD. However, there are several obstacles 
limiting this process, such as the function of the cells in vivo. Moreover, the expansion 
of specific required cells is still difficult according to current defined phenotype and 
technical limitations. [36-39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.5 Hematopoietic stem cells (HSCs) 
Stem cells can be retrieved from bone marrow (BM), peripheral blood (PB) and cord 
blood (CB) [40], as well as from other sources. Bone marrow was the first established 
source for stem cells followed by peripheral blood [41-44]. Cord blood as a stem cell 
source was established later, and is used mainly in pediatric transplantation due to the 
limited cell content. Cord blood is also used in adult transplantation; however, two 
units have to be combined for one recipient [45-47]. Numerous studies have compared 
the three sources of HSCs. The CB was reported to have lower GVHD intensity and 
treatment related mortality [48-49]. However, both Takahashi’s studies related this 
advantage to the established set-up in their transplantation center, such as conditioning 
regimen, GVHD prophylaxis and genetic allo-reactivity between their studied 
populations. One of the advantages of the cord blood is its availability without the need 
B 
B C A 
DP DQ DR 
Class II 
Class I A 
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for a donor to go through the donation procedure. Moreover, cord blood transplantation 
required less histocompatibility matching. However, transplantation of peripheral blood 
or bone marrow from a living donor encounters the ability to repeatedly harvest stem 
cells in case of booster or re-transplantation are required. On the other hand, the 
availability of cord blood matching the first transplant could also be a limiting factor 
[50] for retransplantation after CBT. 
Although no results have shown the advantage of PBSC transplantation over BMT and 
vice versa with regards to relapse, disease free survival, outcome and GVHD, PB 
donation has the advantage of being a less invasive procedure compared to the BM 
donation [51-52]. However, acute (aGVHD) and chronic GVHD (cGVHD) have been 
reported with high incidence after PBSCT [53-54]. PBSCs are more frequently used in 
autologous transplantations compared BM. One of the advantages of the PBSCT over 
the BMT is the faster engraftment, especially in malignant disorders [55-57].        
New sources of stem cells such as adipose tissues are promising for the future of 
transplantation. Stem cells from adipose tissues have some advantages compared to 
other sources, such as its less complicated procedure and its capacity to produce other 
types of cells (for example, mesodermal and non- mesodermal lineages). The adipose 
tissue is also rich in mesenchymal stem cells [58-60]. 
 
1.1.6 Donor types 
There are different types of transplantation depending on the donor. The cells can be 
obtained from the recipient (autologous transplantation). In this case the recipient’s 
own cells are harvested and stored. The recipient then receives an intensive 
conditioning regimen adjusted to the disease, disease stage and co-morbidities. 
Afterward, the recipient receives his or her own stem cells through infusion. The G-
CSF mobilized peripheral stem cell protocol is a standard procedure for an autologous 
transplantation [61-62]. High intensity conditioning has also been used before 
transplantation in the treatment of autoimmune diseases [63-64]. Syngeneic 
transplantation is the transplantation between genetically identical individuals with the 
same histocompatibility antigens, such as monozygotic twins in humans and members 
of the same inbred strain in animals. Because of the high polymorphism of the MHC, 
syngeneic transplantation in humans is rare. There is a very low incidence of GVHD in 
syngeneic HSCT, but there is an absence of graft versus malignant cells effect which 
compromises the outcome of HSCT in malignant diseases, especially in advance stages 
[65-69].   
Allogeneic transplantation is transplantation between individuals within the same 
species, but with genetic disparities. This is a common type of transplantation in human 
due to limited number of identical twins and the benefit of allogeneic HSCT over 
syngeneic for cancer eradication. With a steady increase of transplantation applications 
to cover more diseases and patient groups, the research aims to minimize the 
complications and improve transplantation outcome [70-72]. One approach is to 
decrease the intensity of conditioning regimen and thereby reduce toxicity [73] without 
compromising the outcome. The success of these approaches increases the number of 
patients accepted for HSCT, including older patients including those who have minor 
organ dysfunction [74-76]. Xenogeneic transplantation is transplantation between two 
different species. This type of transplantation is used in special cases (such as 
transplantation of a heart valve), but its application in stem cell transplantation is very 
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limited [77]. Beside the major mismatches between the immune system of different 
species, infection transfer is a major concern that limits the research in this area.  
 
1.1.7 Patient selection for HSCT 
There are specific criteria to consider when determining if a patient is suitable for 
HSCT. These include: health status, disease stage, type of transplantation (autologous 
or allogeneic) and type and dose of conditioning regimen. Details on clinical criteria as 
well as which diseases are suitable for which type of transplantation at which stage of 
the disease are summarized elsewhere [78-83]. 
 
 
1.1.8 Conditioning regimen 
The host immune system has to be suppressed in advance to permit the establishment 
of the donor immune system. Different conditioning regimens have been used to 
suppress the host immune system involving chemotherapy, radiotherapy or a 
combination of both. Anti-thymocyte globulin is sometimes added to the conditioning 
regimen [84-85]. Antineoplastic agents are classified according to cell cycle phase 
specificity and mechanism of action. Based on the  mechanism of action, cytostatics are 
classified as alkylating agents [86-88], antimetabolites [89-90], anthracyclines [91], 
antitumor antibiotics [92], monoclonal antibodies [93] or platinum compounds [94]. 
Several alkylating agents are used in the conditioning regimens. The term alkylating 
agents arose from their ability to alkylate many nucleophilic functional groups. 
Alkylating agents can be divided into two groups according to their mechanism of 
action. The first group functions by forming covalent bonds with the amino, carboxyl, 
sulfhydryl and phosphate groups. The second group of alkylating agents acts by 
irreversibly binding to DNA and thus affecting the replication of DNA resulting in the 
disturbance of fundamental proliferation pathways. However, both groups of alkylating 
agents are cell cycle non-specific. Cisplatin, carboplatin and oxaliplatin are an example 
of the first group and cyclophosphamide, busulfan, chlorambucil, ifosfamide and 
mechlorethamine are examples of the second group.  
Busulfan (Bu) and cyclophosphamide (Cy) in combination is a standard conditioning 
regimen [95] for stem cell transplantation. The introduction of Bu in the conditioning 
regimen reduced the use of TBI. The combination of TBI and Cy is still a common 
conditioning regimen. The combination of both drugs covers a wide spectrum of effects 
as Bu is myeloablative while Cy is immunosuppressive [96]. Bu is given orally or 
intravenously, and the advances in therapeutic dose monitoring has reduced Bu side 
effect [97]. However, individualizing the dose according to the patient’s genetic 
variations is still not feasible [97]. Conditioning regimen Bu-Cy or Cy-TBI is selected 
based on the type and stage of the disease, since each combination has been shown to 
have its specific advantages. The Cy-TBI combination has been reported to have 
advantages in terms of less relapse, fewer transplant related mortality (TRM) and better 
disease free survival (DFS) in patients with acute lymphoblastic leukemia (ALL), 
whereas it has different effects in chronic myeloid leukemia [98-101]. However, the 
engraftment and GVHD occurrence is similar in both conditioning regimens [102].  
The intensity and type of conditioning regimen is selected with regards to patient, 
disease type and stage as well as co-morbidities. Reduced intensity conditioning 
regimen (RIC) is usually considered for older patients [103-105], however, the use of 
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RIC in children is increasing [106-108]. One of the drawbacks after RIC is the 
increased risk of infections [109]. Although a high intensity conditioning regimen 
(myeloablative conditioning) has a higher risk for side effects, it is still the first choice 
in many situations (especially in advanced leukemia). However, intensive research is 
being done for the possible use of RIC or by a combination of conditioning regimens 
that has less toxicity without compromising the transplantation outcome [110]. 
Retrospective studies in patients with acute myeloid leukemia showed that transplant-
related mortality was decreased and relapse was increased in patients treated with RIC, 
instead of myeloablative conditioning [111-112]. Leukemia-free survival was similar in 
both regimens.  
 
1.2 COMPLICATIONS 
Despite of continuous improvement in HSCT, several major complications still 
compromise its outcome. GVHD, sinusoidal obstruction syndrom (SOS) previously 
named as hepatic veno-occlusive disease (VOD) [113-116] and infections are the most 
common complications following HSCT [117]. Other complications after HSCT have 
also been reported, such as mucositis [118], dental development problems [118-120], 
hemorrhagic cystitis [121] and ocular GVHD [122-124]. 
 
1.2.1 Graft versus host disease 
GVHD is a frequent complication that occurs after allogeneic stem cell transplantation 
when the new immune system derived from the donor recognizes the host tissues as 
foreign [125]. GVHD was first characterized in 1957 [126]. Extensive research and 
development of immunosuppressive drugs resulted in improvement of the prevention 
and the treatment of GVHD [127-130]. Nevertheless, GVHD is still the major obstacle 
in allogeneic HSCT whenever the transplantation is involving a high disparity between 
recipient and donor immune systems. Apart from the few reported cases [131], GVHD 
is not considered a barrier in  syngeneic HSCT.  
Specific conditions are required for GVHD to occur: the donor cells must be 
immunologically competent and the host should be immuno- compromised, and the 
host tissues must have histocompatibility antigens that are lacking in the donor cells 
[132-133]. GVHD is defined as acute or chronic according to its manifestation. The 
classical definition of aGVHD is that it takes place within the first 100 days post HSCT 
while cGVHD occurs beyond 100 days post HSCT. However, this is an arbitrary 
definition; acute and cGVHD onset may overlap if biology and symptoms are taken 
into account [134]. The onset of both types of GVHD is affected by the intensity of the 
conditioning regimen, graft type, graft content and immunosuppressant [135-136]. 
Donor lymphocyte infusion (DLI) used to enhance engraftment of donor cells or to 
induce an antileukemic effect may stimulate GVHD [137].  
Acute GVHD is characterized by dermatitis, hepatitis and damage to the 
gastrointestinal tract resulting in abdominal pain and diarrhea [138]. The mechanism 
behind aGVHD has been extensively studied. The aGVHD takes place in three phases 
involving both the innate and the adaptive immune systems. [139-144]. The first phase 
starts when the conditioning regimen damages the host tissues and produce 
inflammatory signals. The gastrointestinal tract is one of the first targeted tissues. The 
tissue injuries translocate the lipopolysaccharides (LPS) to the circulation. LPS 
stimulate the tissues to secrete inflammatory cytokines such as IL-1, TNF-α and INF-γ. 
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The second phase of aGVHD is the stimulation of mature donor T cells to recognize the 
different antigens. This stimulation is achieved through the secretion of adhesion 
molecules and T cells attracting chemokines, as well as by the elevation of MHC 
expression in the inflamed tissues. The third phase is the effector part, which is 
consequence of the accumulation of the events from the two preceding phases. Both the 
innate and the adaptive immunoresponses in this step cause cytolysis. The activated 
macrophages and cytotoxic T lymphocytes start to attack the targeted tissues [140]. 
Figure 5 illustrates the pathophysiology of aGVHD [145]. However, other mechanisms 
that explain the pathophysiology of GVHD (such as early destruction of the host niche) 
have also been reported [146]. 
 
Chronic GVHD is less explored than aGVHD. cGVHD has features similar to 
immunological disorders and autoimmune diseases such as scleroderma, immune 
cytopenias and chronic immunodeficiency syndrome [147]. cGVHD can manifest in 
one organ or it can spread to several tissues. The patients who develop cGVHD may 
have a history of aGVHD. cGVHD can lead to organ dysfunction and life threatening 
complications. Although the mechanisms behind cGVHD are less clear than those in 
aGVHD, there are four suggested pathways for the development of cGVHD. Damage 
to the thymus and effects on the T cell negative selection, decrease in the regulatory T 
cells, uncontrolled production of antibodies and the formation of profibrotic lesions are 
the most probable pathways leading to cGVHD [148]. 
 
Donor T cells are among the cells responsible for acute GVHD through their 
immunological features and recognition of host antigens as foreign molecules. On the 
other hand, depletion of T cells from the graft either ex vivo or in vivo by treating the 
recipient with T cell antibodies such as anti-thymocyte globulin (ATG) can cause graft 
rejection and/or tumor relapse in cases where malignant disease has been the indication 
for transplantation [149-152]. Since donor T cells recognize malignant cells as foreign, 
the graft versus tumor effect is an important parameter of HSCT [153-155]. T cell 
subsets differ in their functional properties. Some of them have cytotoxic functions and 
some have been shown to play a regulatory role. However, the role of each T cell 
population and its involvement in cytotoxicity and regulatory effect has still not been 
totally identified. Within the T cells subsets,  T cells have been reported to be the 
main inducers of GVHD. CD4+ and CD8+ T cells induce GVHD by different 
mechanisms [156-159].  
 
Regardless of the achievements in understanding GVHD, prediction of GVHD 
occurrence is still a major concern. Accordingly, all recipients undergoing HSCT 
receive immunosuppressive treatment (even in the case of HLA matched siblings) to 
prevent GVHD and host versus graft (HVG). At present, several immunosuppressive 
drugs are used in clinical practice. Cyclosporine A (CyA) is one of the most common 
used drugs for GVHD prevention after transplantation; however, these drugs also have 
side effects [158-159].  The golden standard for immunosuppression after HSCT today 
is cyclosporine combined with methotrexate [128, 160]. 
 
New strategies to prevent GVHD have been investigated either directly in vivo or ex 
vivo [161-162]. Soluble Fas ligand, for example, has been shown to enhance activation 
induced cell death when incubated with alloreactive cells before transplantation. This 
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Figure 5: Pathophysiology of GVHD 
method also results in proliferation reduction of allogeneic stimulator responses in vivo, 
improves the graft versus tumor effect and preserves the engraftment capacity of 
allogeneic cells [163]. NKT cells from recipients have been shown to prevent tissue 
inflammation caused by donor T cells, but retain their anti-tumor effect against B cell 
lymphoma. In the same study, the authors showed reduction in the expansion of donor 
T cells in the lymphoid tissues and the colon in aGVHD model [164]. Programmed 
death-1 (PD-1) protein, which belongs to the B7:CD28 superfamily diminished 
alloreactive T cell response after BM transplantation through its negative regulatory 
effect on CD4+ and CD8+ T cells. Therefore, an increase in the expression of PD-1 has 
been suggested to decrease GVHD [165].   
 
 
 
 
1.2.2 Sinusoidal obstruction syndrome  
SOS remains one of the complications following myeloablative HSCT which manifests 
as hyperbilirubinemia, hepatomegaly and fluid retention. SOS damages the hepatocyte 
and the sinusoidal cells in the centrilobular zone of the liver acinus. High doses of   
alkylating agents are responsible for SOS onset, which in severe cases could lead to 
multi organ failure [114, 116, 166-169].  Busulfan is known as one of the main risk 
factors for SOS [170-172]. Regardless of the long history of the disease, there is still no 
efficient curative therapy. Defibrotide is one of the promising therapies now in clinical 
trials [173]. However, since high dose chemotherapy is the initiative cause of the 
disease, reduced intensity conditioning can reduce the damage to tissues and result in a 
lower rate of SOS [174].   
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1.2.3 Rejection and disease relapse 
Rejection occurs when the new immune system cannot compete with the existing 
immune system. When the conditioning regimen is not strong enough to suppress the 
host immune system, host immune cells start to proliferate.  
 
Since T cells are the main cells involved in graft rejection, a lower number of T cells in 
the graft or a high number of residual T cells in the host might result in graft rejection. 
T cells from the donor are important in further eradicating the host cells. Moreover, 
donor T cells are necessary to kill cancer cells in case of malignancy.  However, the 
type of donor cells or residual host T cells is also important in graft rejection. The 
higher number of Treg cells in the graft may help to develop graft rejection and disease 
relapse. Other host residual cells such as natural killer cells (NK) or DCs also 
contribute to graft rejection. An increased histocompatibility mismatch between 
recipient and donor increases the chance of graft rejection when the donor has MHC 
antigens not found in the recipient. Moreover, the RIC also results in higher residual 
cells and thus increases the chance for host cells to proliferate. The correct dosage and 
continuous administration of immunosuppressant limit T cell expansion and help to 
decrease GVHD and rejection [175-176].  ABO blood group matching is also critical; a 
mismatch increases graft failure after unrelated HSCT [177]. In identical HSCT the 
ABO mismatch causes some complications but do not impair the clinical outcome 
[178-180]. Although disease relapse goes hand in hand with graft rejection, disease 
relapse is more dependent on the type and stage of the disease. Moreover, second or 
third transplants are more likely to result in disease relapse [181] as the cancer cells 
develop resistance to the treatment. A greater understanding of the immune system, 
specific targeting of tumor cells and separating them from normal cells will help to 
decrease the frequency of relapse and to separate GVHD from the graft versus tumor 
(GVT) effect [182].  
 
1.2.4 Infections 
Infections after HSCT contribute to morbidity and mortality [117]. There is a high risk 
for bacterial infections during the neutropenic period when the immune system is still 
not recovered. Infection occurrence depends on several factors such as the aseptic 
procedure, type of graft, type of transplantation, the degree of mismatch between 
recipient and donor and the use of anti-infectious treatments. The incidence of different 
bacterial [183], fungal [184-187] or viral infections varies during the post HSCT 
period. Development of new prophylactic agents, post transplantation monitoring of 
infections and better aseptic techniques have resulted in a decreased incidence of 
several infections [188-192]. 
 
1.3 FATTY ACIDS 
Nutrition is an important factor affecting health. Several food components have been 
shown to decrease the risk of various diseases [193-194]. Polyunsaturated fatty acids 
(PUFAs) have been reported to affect the immune system. PUFAs may also modify the 
effects of different therapeutic agents [195]. The efforts to reduce the complications of 
HSCT are ongoing, and food has been highlighted as a factor that affects 
transplantation outcome [196]. Fatty acids are linear hydrocarbon chains with a 
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Figure 6: Omega-3 and omega-6 synthesis 
terminal methyl group called omega (ω) and another terminal with a carboxyl (-COOH) 
group. The names and classifications of fatty acids are based on the number of carbon 
atoms and the double bonds. Fatty acids are classified according to the number of 
double bonds into saturated (no double bond), monounsaturated (one double bond) and 
polyunsaturated (two or more double bonds). The PUFAs are defined as short, medium 
or long chain PUFAs. Omega-3 and -6 are within the latter group as they consist of 
more than 16 carbon atoms. The omega-3 fatty acid has three main derivatives; α-
linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 
The major omega-6 derivatives are: linoleic acid (LA), γ-linolenic acid (GLA) and 
arachidonic acid (AA). Although the human body can synthesize saturated and 
monounsaturated fatty acids, it is unable to produce an amount sufficient for its 
requirements. Thus, it is essential to obtain these acids from external sources. 
Moreover, the conversion of these fatty acids to polyunsaturated fatty acids is low, 
which makes it necessary to obtain the polyunsaturated acids from an external source as 
well [197-198]. ALA can be obtained from various types of vegetable oils and from 
some green vegetables, but the body has a limited capacity for converting this acid to 
DHA and EPA. Accordingly, DHA and EPA intake from other sources is rquired [199]. 
Nutritionists recommend that these fatty acids should be acquired through diet rather 
that supplemental products, since natural food also contains other beneficial elements 
such as proteins and vitamins [199]. Fatty fish such as tuna, salmon and halibut as well 
as fish oil are good sources of omega-3 EPA and DHA. The effects of omega-3 may 
also differ according to its source. Fish species, geographical location, water quality 
and other environmental factors may affect the ratio of omega-3 derivatives and thus 
affect their function [200]. Figure 6 demonstrates omega-3 and omega-6 synthesis 
process. 
Omega-3 fatty acids have 
been shown to affect the 
immune system by altering 
the balance of Th1/Th2 
towards Th2 by the 
suppression of Th1 
development and reduction 
of IFN- production [201-
202]. Omega-3 PUFAs have 
been reported to improve  
endothelial function, protect 
against oxidative DNA 
damage [203] and suppress 
CD4+ T cell function and 
proliferation [204-205]. 
Harbige et al 2003 reported 
that a high intake of PUFA   
has an inhibitory effect on 
adhesion molecule expression, 
antigen presentation and 
lymphocyte apoptosis whereas 
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a low intake could enhance some immune functions [206].  Based on these findings we 
hypothesized that omega-3 PUFA as dietary might affect the outcome of stem cell 
transplantation.  
 
1.3.1 Omega-3 and its mechanisms of action 
It is important to understand how omega-3 works inside the body in order to understand 
its function in different diseases and how to use it for therapeutic purposes. Several 
studies have explained the effect as the incorporation of omega-3 into the cell 
membrane, modulation of intracellular pathways and alteration of gene expression 
[207-208] which may result in the alteration of cell function [209-211]. Omega-3 fatty 
acids were reported to decrease triglycerides and very-low-density lipoprotein blood 
levels in hyperlipidemic individuals [212]. Omega-3 modulates cyclooxygenase (COX)  
activity and alters the membrane and cell fluidity, hence affecting the expression of 
different cell receptors [213]. Omega-3 has been reported to have an effect on prostate 
cancer through the COX-2 pathway [214-215]. The COX-2/prostaglandin E-2 (PGE-2) 
pathway has been reported to be involved in cancer promotion and progression [216]. 
The down regulation of COX-2 results in the decrease of its enzymatic product.    
 
1.3.2 Omega-3 and diseases 
Omega-3 plays an important role in health and disease. A shortage of omega-3 may 
lead to fatigue, poor memory, dry skin, heart problems, depression, and poor circulation 
[217].  
 
1.3.2.1 Neurodegenerative diseases 
Omega-3 has been reported to have beneficial effects on neurological complications 
such as Parkinson’s disease [218], Alzheimer disease and other neurodegenerative 
diseases [219-220]. Although a low level of omega-3 may contribute to the 
manifestation and progress of neurological disorders [221], an extra supply of omega-3 
does not eliminate them. However, there are some indications that omega-3 improves 
cognitive decline and dementia. Omega-3 might help to suppress disease development 
at an early stage, but does not seem to reverse the disease at an advanced level [222-
225]. Thus, omega-3 seems to function protectively rather than as a treatment for 
neurodegenerative syndromes [226].  
 
1.3.2.2 Omega-3 and cancer 
The role of nutrition in cancer has become recognized during the recent years because 
of its impact on cell content and its interaction with several drugs, that might affect 
treatment efficacy. Omega-3 is one of the nutritional elements being studied, and it has 
been found to have potential to decrease tumor development and increase treatment 
efficacy [198, 200, 227]. Omega-3 has been reported to have a protective effect as well 
as a suppressive function toward the development of many types of solid tumors such 
as breast [228-230], colorectal [213] and prostate cancer [214, 231]. There is no clear 
evidence of an effect of omega-3 in hematological malignancies. However, some 
reports show that omega-3 have an effect on the growth suppression of leukemia cells 
in vitro [232-234].  
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1.3.3 Omega-3 and cytostatics  
Omega-3 has been reported to enhance drug efficacy and to facilitate drug uptake in 
cancer chemotherapy. Omega-3 supplementation in combination with various 
chemotherapies has been shown to decrease tumor size and prolong patient survival 
with lower side effects [235-239]. Omega-3 may enhance tumor response to cytostatic 
agents in the treatment of breast cancer. The amount of omega-3 found in breast 
adipose tissue was correlated with the response to chemotherapy [240]. 
Cyclophosphamide widely used in the treatment of leukemia, lymphoma and solid 
tumors [241]. Cyclophosphamide is a pro-drug and is converted to active metabolites in 
the liver [242]. Growth inhibition of cancer cells by cyclophosphamide and/or its 
metabolites has been shown to be significantly enhanced by omega-3 [239]. In contrast, 
there is no report on the effect of omega-3 on busulfan function.   
 
1.3.4 Omega-3 and inflammation 
Omega-3 is among the most potent immunomodulatory and anti-inflammatory PUFAs. 
The lower incidence of autoimmune and inflammatory diseases in Greenland Eskimos 
(Upernavik district) and Japanese populations point out the importance of omega-3 and 
implicates that an increased intake of fish may protect against several diseases. In both 
populations, especially Greenland Eskimos, a higher ratio of long chain omega-3 
PUFAs was found compared to other studied (mainly western) populations [243-245]. 
Inflammation is a complex biological process initiated by the innate immune system as 
a response to infection, tissue damage or other stimulus. Inflammation occurs in 
vascular tissues and the process involves various chemokines, cytokines and 
leukocytes. Although the process is a protective mechanism for the body, it may be 
harmful when it is out of control. The process requires the movement of leukocytes 
from the blood stream to the injured tissues through the blood vessels. In this process 
the recruited leukocytes migrate and adhere to the endothelial cells. The inflammation 
itself results in the expression of inflammatory products followed by antagonists in 
order to control the inflammation. Unresolved inflammation may lead to various types 
of diseases. Within a short time after the initiation of the inflammatory response, the 
process to resolve the inflammation begins. The granulocytes themselves promote 
prostaglandins and leukotrienes that have been derived from arachidonic acid to 
lipoxins. Omega-6 provokes the inflammatory process by supporting leukocyte 
adhesion and transmigration across the endothelial cells through the generation of the 
prostaglandin D2 (PGD2). Omega-3 prevents the progression of this process through 
the generation of prostaglandin D3 (PGD3) which antagonizes PGD2. Moreover, 
omega-3 reduces the expression of vascular cell adhesion molecule 1 (VCAM-1), E-
selectin, the intercellular adhesion molecule 1 (ICAM-1) and inflammatory cytokines, 
which all promote the transmigration of the leukocyte [246-249].   
 
1.3.5 Omega-3 and transplantation 
Although omega-3 is extensively studied in many inflammatory disorders and in some 
cancer treatments, only a few studies have reported the effects of omega-3 on the 
outcome of HSCT. Thus, the benefit of omega-3 supplementation to transplanted 
patients is uncertain [250], due to limited data and the fact that HSCT is a complex 
procedure involving many factors. Transplantation involves the immune system, 
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immunosuppressive agents, conditioning regimen, disease type and patient status. 
Moreover, the amount of omega-3 used and the duration of treatment both influence the 
effect, something which is mirrored by the reported contradictory data. Nevertheless, 
some studies report benefits from omega-3 in at least some stages of the transplantation 
procedure inasmuch as omega-3 suppresses the inflammatory situation and may reduce 
drug toxicity. Apart from the two publications by Takatsuka 2001 [251] and 2002 
[252], there are no further detailed studies on the effect of omega-3 on HSCT. The first 
study reported significant benefits from EPA supplementation and showed better 
survival in EPA treated patients, which was explained by reduced inflammation. The 
second study assessed the action of aGVHD indirectly by measuring the level of 
leukotriene (LT) B4 and several inflammatory cytokines. The study reported beneficial 
effects from EPA on aGVHD. However, both studies had a limited number of patients, 
and thus, the results are not fully conclusive.   
 
1.4 REGULATORY CELLS 
Many kinds of regulatory cells are naturally presented in the body or produced upon 
stimulation of the immune system. The conventional regulatory cells of the immune 
system are T cells that have the CD4+CD25+ phenotype and are developed by the 
thymus or in periphery. The intracellular transcription factor forkhead box P3 (FoxP3) 
has been reported as an essential marker for the development and suppressive 
properties of Treg cells [253]. However, natural and induced Treg cell populations have 
an important function in immune regulation [254]. Treg cells are also defined by other 
markers that differentiate them from other T cells in that they have lower or absent 
expression of CD127 surface antigen. However, other cells than CD4+ have also been 
reported to have regulatory functions, such as CD8+ Treg cells [255-258]. The different 
types of Treg cells have different potentials and play a major role in immune tolerance 
and immune homeostasis through different mechanisms. Regulatory cells have 
therapeutic potential, especially in transplantation tolerance [259-260]. Production of 
regulatory T cells in cell culture suppresses CD8+ T cell mediated cytotoxicity through 
the exhibited suppressive properties presented as proliferation suppression, inhibition of 
perforin and granzyme B lyses pathway [261]. 
 
1.4.1 Regulatory cells and diseases 
Regulatory T cells play an important role in the maintenance of tolerance and are key 
factors in different types of diseases [262]. Hence, the impairment of Treg function has 
been reported to be involved in autoimmune [263], infectious and other inflammatory 
diseases. Defective ability of Tregs to suppress T cell proliferation was reported in 
several autoimmune diseases. Treg cells have also been reported to have defective 
suppressive capacity in multiple sclerosis [264-266], diabetes [267] and rheumatoid 
arthritis [268-269].  
 
1.4.2 Regulatory cells and transplantation 
Transplantation processes involve two immune systems and the acceptance of the 
transplant is dependent on the degree of histocompatibility matching. T regulatory cells 
are involved in tissue tolerance. The host considers the alloantigens from the donor as 
foreign and hence initiates an immune response against them. Immunosuppressants as 
external regulators protect the transplanted tissues from rejection and at the same time 
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protect the host from the transplanted cells. Immunosuppressive agents that have been 
used to suppress the immune system do not have long life supportive capacity, and they 
have to be continuously administered to the patient. Moreover, these drugs also have 
side effects and might contribute to organ failure. The long term complications of 
HSCT  are still a major challenge; thus, there are several approaches to using Treg for 
therapeutic purposes in HSCT [270]. Consequently, it is necessary to better understand 
the natural regulatory mechanism of tolerance in order to lower side effects and 
improve transplantation outcome [271]. The immune response is controlled by 
regulatory cells in different ways. Treg cells may directly suppress the effector T cells.  
 
The number and function of regulatory T cells affect the severity of GVHD [272]. Treg 
cells have been reported to attenuate GVHD after HSCT without compromising the 
graft versus tumor effect [273]. However, the effect is more pronounced in aGVHD 
compared to cGVHD [274]. Recently, several approaches using Treg cells for 
prevention or treatment of GVHD have been reported. The donor alloreactive T cells 
may cause GVHD, but the uncontrolled depletion of T cells may end in graft rejection. 
So, the new approach is to have selective donor T cells to preserve graft tolerance, to 
reduce the risk of infection and at the same time to prevent the development of GVHD. 
The induction of Treg cells in HSCT reduces GVHD while their depletion from the 
graft intensifies it. Figure 5 illustrates the role of Treg cells in the modulation of 
GVHD.  
    
1.4.3 The effect of omega-3 on regulatory cells  
Treg cells carry a high therapeutic potential in the transplantation field and in other 
immunological processes. It is important to understand factors that may affect the 
effectiveness of their function. Omega-3 has been reported to have an important role in 
different metabolic, inflammatory and autoimmune diseases, so it is of interest to study 
omega-3 impact on the regulation of the immune system. Omega-3 may exert its effect 
through the modification of various mediators or balancing of fatty acids in the cell 
membrane. Omega-3 has been reported to increase the induction of Treg cells through 
the activation of peroxisome proliferator activated receptor γ (PPARγ) [275-276]. The 
results of sveral studies on the effect of omega-3 in solid organ transplantation were not 
consistent, but some of the studies reported a beneficial outcome and prolonged 
survival [277-280]. Other studies reported no influence of omega-3 on acute rejection 
[281] or long term survival [281-282]. Since the majority of these studies used 
immunosuppressants concomitantly with omega-3, it is difficult to draw a conclusion 
on the direct effect of omega-3 on the immune system.  
 
1.5 STEM CELL TRANSPLANTATION AND VASCULAR TOXICITY 
Late lethal complications have been reported after stem cell transplantation [283-284]. 
Vascular toxicity is one of the adverse effects that may be involved in late 
complications such as congestive heart failure (CHF) and other cardiovascular 
complications [285]. It is difficult to correlate the early events to the late vascular 
complications after HSCT due to multiple factors that might be involved in the 
development of these complications. These factors include the patient individual 
disposition to vascular diseases, different conditioning regimens, different grafts, 
immunosuppressive drugs, nutrition, life style, etc. With an increased number of long 
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term survivors, the number of late complication is also increasing and thus better 
understanding of the early events in vascular toxicity is urgently required.  Moreover, 
the numbers of elderly patients undergoing HSCT is increasing, which means that the 
risk of cardiovascular complications is increasing among this population as well [286-
287]. A better understanding of the risk factors may help to reduce the late 
cardiovascular problems, especially in elderly patients and in patients at high risk of 
cardiovascular diseases such as hypertension or atherosclerosis.  
 
1.5.1 Vascular system  
The vascular system is made up of vessels with different functions and properties. It 
consists mainly of two types: the arteries and the veins. The aorta is the main artery and 
leads blood from the heart to the rest of the body. As the vessels branch to body tissues 
their size decrease. Defects in the vascular system cause different types of disease 
which might result in various organ defects including cardiovascular complications. 
Peripheral artery disease [288], pulmonary arterial hypertension [289] and  renal artery 
stenosis [290-291] are examples of circulatory system defects. 
  
1.5.2 Nitric oxide and the vascular system  
Nitric oxide (NO) is involved in several biological processes and has been reported in 
cardiovascular disease [292]. NO was described in 1980 as a potent relaxant of vascular 
smooth muscle [293]. It interacts with different mechanisms in the body. NO is 
synthesized from L-arginine in a process that is catalyzed by nitric oxide synthase 
(NOS).  NO is synthesized in different tissues such as endothelial and neuronal cells. 
There are three types of NOS; neuronal NOS (nNOS = NO I), inducible NOS (iNOS = 
NOS II) and endothelial NOS (eNOS = NOS III) [294].   
 
1.5.3 Effect of conditioning regimen 
Conditioning regimen prior to HSCT facilitates the establishment of the new donor 
cells. Approximately half of the patients undergoing HSCT are conditioned with 
chemotherapy. Chemotherapeutic agents used in cancer treatment have been correlated 
to serious cardiac complications [295-296]. Bu and Cy are commonly used in 
conditioning regimen prior to HSCT [297-298]. Cy is also used in many cancer 
treatment protocols [299] and in low doses in the treatment of several autoimmune 
diseases [300-301]. Treatment with Cy has been correlated to cardiac toxicity and other 
tissue damage. Although the cardiotoxicity was positively correlated with the dose of 
Cy [302], the symptoms usually appear 10 to 20 years after HSCT in long term 
survivals [286]. However, cardiac failure has also been reported within weeks of Cy 
exposure [303].  Bu, in contrast, has not been reported to be associated with vascular 
toxicity, but has been suggested to play a causative role in pericardial fibrosis [304]. 
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2 AIMS 
The present thesis aimed to increase the knowledge of the mechanisms underlying 
graft versus host disease in stem cell transplantation following busulfan - 
cyclophosphamide conditioning regimen.  
  
SPECIFIC AIMS   
 
 To study the early expansion of donor cells after allogeneic 
hematopoietic stem cell transplantation (HSCT). 
 To correlate cell activation and cytokine expression with onset and 
intensity of graft versus host disease (GVHD). 
 To study the dynamic changes of the histopathology of the liver, spleen, 
lung, kidney, heart and pancreas after allogeneic compared to syngeneic 
stem cell transplantation. 
 To investigate the effect of busulfan - cyclophosphamide (Bu-Cy) 
conditioning regimen on the  physiological properties and structure  of 
the mesenteric arteries and  aorta 
 To study the effect of omega-3 on the efficacy and toxicity of Bu-Cy 
conditioning regimen. 
 To study the effect of omega-3 on immunological response and on the 
onset and intensity of GVHD. 
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Table 1: Criteria for GVHD after HSCT 
3 MATERIALS AND METHODS 
3.1 ANIMALS 
The mice were 8 to 12 weeks old and were purchased from Scanbur (Sollentuna, 
Sweden). They were maintained under pathogen-free conditions with controlled 
humidity (55 ± 5%), 12 hours light/dark cycle, balanced temperature (21 ± 2
o
C), and 
HEPA-filtered air. The animals were kept in individually ventilated cages and were 
fed autoclaved chow and tap water ad libitum. They were acclimatized for 1 to 2 
weeks before the start of the experiment.  
All animal experiments were approved by the southern ethical committee and in 
accordance with the Animal Protection Law, the Animal Protection Regulation and the 
regulation of the Swedish National Board for Laboratory Animals.  
 
In the syngeneic setting female BALB/c (H-2K
d
) were used as recipients and male or 
female BALB/c mice were used as donors. While in the allogeneic setting BALB/c 
mice were used as recipients and male C57Bl/6 (H-2K
b
) were used as donors. 
Untreated mice were used as controls whenever appropriate. 
The mice were weighed and their health status was assessed as described in detail in 
each study. In experiments entailing GVHD, the recipient mice were weighed every 
day and GVHD scored every other day. GVHD was scored using the following criteria 
[305] described in table 1: 
 
Criteria Grade 0 Grade I Grade II 
Weight lost < 10% 10 to 25% >25% 
Posture position Normal Hunching but not during 
movement  
Severe hunching 
effecting movement 
Activity Normal Mildly to moderately 
decreased 
Stationary unless 
stimulated 
Fur texture Normal Mild to moderate ruffling Severe ruffling/poor 
grooming 
Skin integrity Normal Scaling of paws/tail Obvious areas of 
denuded skin 
For the last study evaluating the effect of Omega 3, animals in different groups were 
fed one of the following diets: 1) Omega-3 (from menhaden fish oil) 10% supplement, 
2) Corn oil (10%) supplement or 3) Standard food. The animals in all the groups had 
access to their food ad libitum for three or eight weeks respectively. The corn oil diet, 
which is the source of omega-6, was given as a control for the fat effect.  
 
3.2 ANTIBODIES 
Fluorescein isothiocyanate-(FITC) conjugated H-2K
b
(clone: AF6-88.5), H-2K
d
(clone: 
SF1-1.1), CD3 (clone: AF6-88.5), NK (clone: DX5), CD44 (clone: IM7), Ia-IE (clone: 
2G9) and Phycoerythrin-conjugated (PE) conjugated H-2K
d
(clone:SF1-1.1), CD8 
(clone: 53-6.7), H-2K
b
(clone: AF6-88.5) and PerCP-Cy5.5 conjugated CD3 (clone: 
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Figure 7: Schematic diagram for Bu-Cy conditioning regimen and HSCT 
145-2C11), CD25 (clone: PC61), CD11b (clone: M1/70) and APC conjugated CD4 
(clone: RM4-5), CD19 (clone: 1D3), CD62L (clone:MEL-14), CD11c (clone: HL3) 
and FC-receptor blocking monoclonal antibody (clone: 2.4G2) were purchased from 
BD Pharmingen (BD Biosciences, Stockholm, Sweden).  
 
3.3 CONDITIONING REGIMEN 
Busulfan and cyclophosphamide were purchased from Sigma-Aldrich (Sigma-Aldrich 
Stockholm, Sweden). Busulfan was dissolved in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich) at a concentration of 40mg/ml and was stored at room temperature (RT). 
Cyclophosphamide was dissolved in sterile water at a concentration of 10mg/ml and 
stored at RT. Both drugs were further diluted to working sultion using PBS . Each 
mouse received 20mg/kg/day x 4 days of busulfan followed by 100mg/kg/day x 2days 
of cyclophosphamide (Figure 7). Both drugs were administered via intra-peritoneal (IP) 
injection. 
 
 
 
 
 
 
 
3.4 BONE MARROW TRANSPLANTATION PROCEDURE 
3.4.1 Tissue harvesting 
Donor mice were killed by cervical dislocation and then placed on their backs on clean, 
dry and absorbent paper. The mouse skin and fur was cleaned with 70% ethanol to 
disinfect the area and reduce the possibility of contamination. A mid abdominal 
incision was made with scissors and forceps. The skin was detached from the peritoneal 
wall. Using sterilized forceps and scissors, the abdomen and peritoneal area were 
explored carefully. The spleen was removed and placed in a cold 2% FBS/PBS 
(phosphate buffer saline; PBS, and fetal bovine serum; FBS), which were purchased 
from Invitrogen (Invitrogen AB, Stockholm, Sweden). Both femurs and tibias were 
aseptically removed and placed in cold 2% FBS/PBS. 
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3.4.2 Cell preparation 
The spleens from the donor mice were placed one by one in sterile Petri-Dishes and cut. 
The cells were re-suspended in 2% FBS/PBS containing 0.01 mM EDTA, then passed 
through a 70 μm cell strainer into a 50 ml conical tube. The syringe plunger was gently 
used to disintegrate cell clumps. 
 
Femurs and tibias were cleaned from soft tissues by sterile mesh and then placed in a 
clean Petri-Dish containing sterile PBS. The bone marrow was flushed with 5 ml 2% 
FBS/PBS containing 0.01 mM EDTA into 50 ml conical tube. Single cell suspension 
was prepared by gently mixing the cell suspension using a 14G needle attached to a 5 
ml syringe. 
 
The pooled cells from either spleens or BM were counted separately using Türk and 
Trypan Blue solutions to assess the total number of nucleated and viable cells. 
Appropriate numbers of BM and SP cells were passed through a 70 μm cell strainer 
before transplantation. The final volume of the graft was adjusted to 200 μl of cell 
suspension per mouse. 
 
3.4.3 Transplantation  
2 x 10
7
 BM cells and 3 x 10
7
 spleen cells in a volume of 200 μl were injected through 
the lateral tail vein. Transplantation day was assigned as day 0, the days before 
transplantation were numbered with a negative sign (-) and the days after 
transplantation were numbered with a positive sign (+).  
 
3.5 TISSUE ANALYSIS 
PB, spleen, femur and other studied tissues were collected for analysis at appropriate 
time points according to each study design.   
 
3.5.1 Immunophenotyping 
Surface markers: The mouse was placed in the mouse holder and a small cut was made 
in the tail vein using a clean sharp scalpel. Around 50 μl of the peripheral blood was 
sampled either by dropping the blood into an Eppendorf tube (pre-filled with 20 μl 0.5 
mM EDTA or citrate) or by collecting the blood using a needle and syringe. Samples 
were then transferred into FACS tubes. Fc-blocker was added to the cells and then 
incubated for 15 minutes at 4
o
C. The cells were incubated with the appropriate 
antibodies for 30 minutes at 4
o
C. 1 ml of 1X RBC lysing buffer (BD Biosciences, 
Stockholm, Sweden) was added and then the samples were incubated at room 
temperature for 20 minutes in dark place. 2 ml of PBS were added and then the samples 
were centrifuged for 7 minutes at 350 g. The supernatant was discarded and the cells 
were then re-suspended in 200 μl of PBS. The samples were analyzed using FACS 
calibur (BD biosciences) and CellQuest software.   
 
FoxP3 intracellular staining: Single cell suspension was prepared as above. Red blood 
cells (RBC) were lysed with ammonium chloride and then washed twice with PBS. The 
cells were incubated with Fc-blocker at 4
o
C and stained with antibodies against surface 
markers. The cells were then washed and permeabilized in BD Perm/Wash solution 
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(BD Biosciences), after which they were washed with the same solution and stained 
with intracellular staining for PE-FoxP3 antibody (ebiosciences, clone: FJK-16s). 
 
3.5.2 Mixed Lymphocyte Culture (MLC) 
Regulatory T cell function was assessed with MLC. Regulatory T cells were prepared 
from the spleens of female BALB/c mice. Red blood cells in single cell suspension 
were lysed by ammonium chloride. The cells were washed in PBS, after which 
CD4+CD25+ regulatory T cells (Treg) were isolated using Miltenyi Biotec (Fisher 
Scientific, Göteborg, Sweden) mouse isolating kit according to the manufacturer’s 
recommendations. Spleen cell suspension from female BALB/c mice was used as 
responder (Tresp) cells. The Tresp cells were stimulated with anti-mouse CD3e (BD 
biosciences, Stockholm, Sweden) at two different concentrations (3µg/ml and 
10µg/ml). Different ratios of Tresp to Treg were used as follows; 1: 1 (1 x 10
5
 Tresp: 1 
x 10
5
 Treg), 1: 0.5 (1 x 10
5
 Tresp: 5 x 10
4
 Treg) 1: 0.25 (1 x 10
5
 Tresp: 2.5 x 10
4
 Treg). 
One µl of 
3
H thymidine (0.037 MBq/µl) was added to each well in the mixed 
lymphocyte reaction (MLC) plate on day 4. After 18 hours, 100 µl of the supernatant 
was taken carefully from each well for cytokine measurement. The cells were harvested 
on filter with a Cell Harvester (Skatron Instruments Ltd, Suffolk, UK) and allowed to 
dry overnight at RT. The activity was measured in scintillation fluid (OptiScint Hisafe) 
using a liquid scintillation counter (WALLAC, EG&G Comp, Turku, Finland).  
 
3.5.3 Histology and immunohistochemistry 
For the histology staining, tissue samples were fixed in 4% formaldehyde for one day 
and then transferred to 70% ethanol. The tissue was dehydrated and embedded in 
paraffin. The tissue were sectioned and stained in Hematoxylin and Eosin solution 
using the Tissue Tek Prisma (Sakura Finetek Inc, Torrance, CA, USA) automated slide 
stainer. For the immunohistochemistry, the tissue were covered in cryo-embedding 
media (OCT) and frozen on dry ice cooled N-hexan. The tissue was stained with CD4 
(RM4-5) and CD8 (53-6.7) antibodies from BD Pharmingen (San Diego, CA, USA). 
Tissue was cut into 4-5 μm slices, fixed in cold (−20oC) acetone for 3 minutes and 
left to dry overnight. The tissue was rinsed with PBS, and treated with 3% H2O2 in 
methanol and blocked by 4% goat serum in PBS. Primary antibodies were diluted in 
the blocking solution and applied at 4
o
C for one hour. After rinsing in PBS, a biotin-
labeled secondary goat anti-rat antibody was applied. Sections were incubated with 
ABC-HRP complex (BD Pharmingen). Binding sites were visualized with 
diaminobenzidine/hydrogen peroxide. The slides were re-stained with hematoxylin. 
 
3.5.4 Colony forming unit assay 
Mice fed with omega-3, corn oil or standard food were killed and single cell 
suspensions were prepared from bone marrow. BM cell were treated in vitro with Bu in 
final concentration of 20, 40 or 60 µg/ml for 4 hr. Twenty thousand nucleated cells 
were plated in 1.1 ml MethoCult M3434 medium in 35 mm Petri dishes in duplicates. 
Dishes were incubated at 37°C with 5% CO2 and 95% humidity. Colony forming unit- 
granulocyte-macrophage (CFU-GM) was scored at day 12 using an inverted 
microscope. CFU-GM was defined as consisting of 50 or more cells.  
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3.6 ASSESSMENT OF VASCULAR SYSTEM 
Mice were conditioned with 80 mg/kg Bu for four days followed by 200 mg/kg Cy for 
two consecutive days. Five days after the last injection mice were sacrificed by cervical 
dislocation and the heart, aorta and mesentery were dissected and placed in ice-cold 
Calcium free physiological salt solution (Ca0PSS, composition in mmol/L:  NaCl, 119; 
KCl, 4.7; MgCl2, 1.2; KH2PO4, 1.2; NaHCO3, 25; glucose, 11; Na2EDTA, 0.03).  The 
small mesenteric arteries (2-3 loops of the intestine with radial arteries up to the stub of 
the superior mesenteric artery intact) and the aorta were stored for a maximum of 3 
hours on ice before the start of the experiment. The weight of the heart was related to 
the body weight as determined at the time of sacrifice. Right ventricular and left 
ventricular weights (including septum) were also determined.   
 
3.6.1 Physiological study 
Radial intestinal arteries (arteries running perpendicular to the surface of the intestine) 
or their first order branches were used in the present experiment. Using 
ophthalmological quality instruments, the arteries were freed by careful dissection of 
adhering fat, connective tissue and the accompanying vein. After making a small 
incision into the free wall of the micro-artery, two stainless steel wires (diameter 40μm) 
were introduced into the lumen of the micro-artery, taking care not to scrape the intima 
or to stretch the preparation longitudinally.  Approximately 1 mm of preparation was 
thus transferred with 2 luminal stainless steel wires to a 5 ml organ bath in a small 
vessel myograph (DMT A/S, Skejby Science Crt, Aarhus N, Denmark).  The two wires 
were then tightened parallel and under tension with screws on two specimen holders, 
one attached to a linear actuator, the other to an isometric transducer, for registration of 
circumferential isometric force. The organ bath was filled with 5 ml Ca0PSS and the 
actuator was moved carefully until a small amount of isometric force was registered. 
The internal circumference of the vessel at which this force was obtained was recorded 
and labeled “slack circumference”. The next step varied according to the experimental 
protocol. An identical procedure was followed for the distal part of the thoracic aorta, 
except that rings (approx. 2 mm width) were mounted on two parallel stainless steel 
pins (0.2mm diameter). Solutions were freshly prepared, pre-oxygenated (95 % O2
2
- 5 
% CO2
2
) solutions and heated to 37 °C before use.  The solutions in the organ baths 
were oxygenated with the same gas mixture and also kept at 37 °C. 
 
3.6.2 Length-Force measurement 
Having obtained slack circumference for both aorta and mesenteric micro vessels in 
Ca0PSS, the preparations were equilibrated in CaPSS (CaCl2, 2.5mmol/L) for 30 
minutes.  Then the vessels were challenged every 5 min for 60 s with KPSS (CaPSS 
with isotonic replacement of Na
+
 with K
+
, final K
+
-concentration 125 mmol/L). For 
mesenteric micro vessels, the peak of the KPSS-induced contraction (coming within 15 
seconds of application of KPSS) was subtracted from the mean value of the baseline as 
obtained during 30 s preceding the KPSS-challenge (Kact). For the aorta, the value of 
the KPSS-induced contraction at 60 s was used for Kact as there was, in most instances, 
no clearly discernable peak early in the contraction.  After the 2
nd
 KPSS-challenge, the 
internal circumference was stepwise increased by 0.2 mm (0.8 mm for aorta) once 
approximately 2 min after the KPSS-challenge. Once Kact was equal to or lower than 
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Figure 8: Myograph record of length-force relation followed by noradrenalin step 
contractions. 
the preceding value, the internal circumference was reduced by 0.1 mm (micro vessels) 
or 0.4 mm (aorta). The internal circumference at this stage was also recorded and 
labeled optimal internal circumference (ICopt). When the complete length-force relation 
was not determined, the vessels were stretched to their ICopt in Ca0PSS immediately 
after determining the slack internal circumference and were then equilibrated for at 
least 30 min in CaPSS before the start of the experimental protocol. 
 
3.6.3 Contractile and relaxant agonists  
U46619 noradrenalin (Sigma-Aldrich) and endothelin-1 (Bachem AG, Bubendorf, 
Switzerland) were applied cumulatively with log-step increases in concentrations.  The 
zenith at every concentration was subtracted from the baseline and expressed as % of 
the Kact at ICopt obtained in the same vessel. Acetylcholine-, sodium nitroprusside- and 
forskolin- (Sigma-Aldrich) induced relaxations were initiated from a stable contraction 
induced by noradrenalin (between 1 and 30 μmol/L).  Concentrations were applied 
cumulatively with log-steps increases.  From the nadir at each concentration, the stable 
contraction obtained by noradrenalin before the applications of the vasodilators was 
subtracted. This value was then normalized to the maximal relaxation (obtained by 
adding 1 mmol/L sodium nitroprusside and 0.2 mmol/L papaverine (Sigma-Aldrich) in 
Ca0PSS at the end of the experiment and expressed as % of this maximal relaxation. 
The following diagram is an example from a Bu-Cy treated mouse. Figure 8 shows 
length-force measurements followed by noradrenalin steps contractions.  
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Figure 9: Myograph record of blood pressure from a control group animal 
(A) and from a Bu-Cy conditioned mouse (B) 
 
3.6.4 Blood pressure 
The mice were anaesthetized with isofluran (2.6 %; Univentor 400, AgnThos, 
Stockholm, Sweden) and placed on a servo-controlled heating pad maintaining body 
temperature at 37.5 ºC. Blood pressure was measured with a fiberoptic transducer 
(Samba 420/360, Samba sensors AB, Västra Frölunda, Sweden) inserted in the left 
carotid artery. After 15 minutes of stabilization, the pressure was continuously sampled 
during 10 minutes for later analysis. Figure 9 represents an example for blood pressure 
from a control animal (A) and an animal from the Bu-Cy treated group (B). 
 
3.6.5 Measurement of the endothelial nitric oxide synthase (eNOS) 
expression  
The mRNA expression was determined with RT-PCR. Total RNA was isolated from 3 
– 5 mg of frozen mesenteric artery and aorta using RNeasy Mini Kit (Qiagen, Valencia, 
CA, USA) according to manufacturer’s protocol. Total RNA (62 ng from mesenteric 
artery and 180 ng from aorta) was reverse-transcribed using iSCRIPT
TM
 cDNA 
synthesis kit (Bio-Rad, Hercules, CA, USA). cDNA samples were amplified using 2x 
SYBR Green PCR Master Mix (Bio-Rad) at optimal concentrations (10 nmol/L) of 
primers in a total reaction volume of 20 µl under the conditions recommended by the 
manufacturer. Expression levels of genes were normalized to that of ribosomal RNA 
S18 to control for input gene. Samples were assayed in duplicate using expression 
profiles generated using the comparative Ct method implemented in the Applied 
Biosystems 7500 Real-Time PCR System. The following primers were used (5’to3’): 
eNOS F: CCTTCCGCTACCAGCCAGA,  
eNOS R: CAGAGATCTTCACTGCATTGGCTA,  
S18 F: CGCGGTTCTATTTTGTTGGT and  
S18 R: AGTCGGCATCGTTTATGGTC. 
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3.6.6 Western Blot 
For Western Blot analysis, 3 – 5 mg of arterial tissues were homogenized in 100 µl ice-
cold buffer containing: 50 mM Tris.HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 5 mM 
EDTA, 1 mM Na3VO4, 20 mM NaF and a protease inhibitor cocktail (Roche GmbH, 
Mannheim, Germany), 1 mM dithiothreitol (DTT) and 1 mM Phenyl- methylsulfonyl 
fluoride (PMSF). Homogenates were cleared by centrifugation (13,000 rpm; 15 min, 
4°C) and the protein contents of the supernatant were determined using Bio-Rad 
Protein Assay (Bio-Rad. Laboratories, ON, USA). Samples were prepared in 4x 
NuPAGE LDS sample buffer, 10x NuPAGE reducing agent (Invitrogen) and heated for 
10 min at 80°C before electrophoresis. 5 and 30 µg of proteins from mesenteric artery 
and aorta, respectively, were separated on 10 % SDS-PAGE followed by transfer to a 
PVDF membrane. Membranes were blocked for 1 hour at room temperature in TBST 
containing 5% non-fat dry milk or BSA followed by incubation with eNOS or ß-Actin 
antibodies. Membranes were washed with TBST buffer (0.01% Tween-20) followed by 
incubation with HRP-IgG antibodies. Membrane blots were then exposed to ECL 
detection reagents (SuperSignal West Pico Chemiluminescent Substrate; Pierce) and 
visualized using x-ray films. Band intensities were quantified by using Quantity One 
software (Bio-Rad Laboratories, ON). All antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). 
 
3.6.7 Transmission electron microscopy (TEM) 
Mesenteric vessels were dissected as above and pieces were fixed in 2.5% 
glutaraldehyde + 1% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 at room 
temperature for 30 min and stored in the fixative at 4 
o
C. Specimens were rinsed in 0.1 
M phosphate buffer, postfixed in 2% osmium tetraoxide in 0.1 M phosphate buffer, pH 
7.4 at 4
o
C for 2 hours, dehydrated in ethanol followed by acetone and embedded in LX-
112 (Ladd, Burlington, Vermont, USA). Semi-thin sections were cut, stained with 
toluidine blue and used for light microscopic analysis. Ultrathin sections 
(approximately 40-50 nm) were cut and contrasted with uranyl acetate followed by lead 
citrate and examined in a Tecnai 12 Spirit Bio TWIN transmission electron microscope 
(Fei Company, Eindhoven, The Netherlands) at 100 kV. Digital images were taken 
using a Veleta camera (Olympus Soft Imaging Solutions, GmbH, Münster, Germany). 
 
3.6.8 Statistical analysis 
Graph prism version 4, SPSS version 16 were both used for graph design and data 
analysis. Student t-test was used for the comparison between two groups. Other 
analysis tests were used as indicated in each study. Results consider significant when 
the P < 0.05. 
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Figure 10: BM and spleen cellularity from syngeneic (connected open signs) and 
allogeneic (connected filled signs) transplantation 
4 RESULTS 
4.1 STUDY I 
4.1.1 BM and spleen cellularity 
Bu-Cy conditioning [306] resulted in a 95% and 63% decrease in bone marrow and 
spleen cellularity, respectively. This conditioning significantly reduced most of the cell 
populations with the exception of some T subpopulations that showed resistance to the 
conditioning regimen. The CD11b+ myeloid cells were the most affected in BM while 
B cells were the most affected in spleen. We assessed the bone marrow cellularity 
within 21 days post HSCT in syngeneic and allogeneic settings. In syngeneic settings, 
the recovery of cellularity in both tissues started earlier and increased until full recovery 
in the BM and over 70% recovery in the spleen within three weeks. In contrast, the 
allogeneic HSCT showed a delayed recovery in both tissues and never reached normal 
levels (Figure 10).  
 
 
4.1.2 Expansion and phenotype of immune cells 
Early expansion of natural killer (NK) cells was observed in syngeneic and allogeneic 
HSCT and reached an expansion peak at day +3. NK cells declined within the next 
days post transpation in syngeneic and allogeneic settings. In the syngeneic HSCT, NK 
cells expanded until full recovery while they continued to decrease in allogeneic HSCT 
(Figure 11A). Dendritic cells followed a pattern similar to that seen in NK cells. 
Interestingly, the expanding DCs were of donor origin while the host DCs decreased 
gradually (Figure 11B, F) . CD8+ T cells increased to reach maximal expansion at day 
+5 after allogeneic HSCT in BM and spleen. CD8+ T cells from BM and spleen were 
decreased in the syngeneic setting, in contrast to the allogeneic setting (Figure 11 D). 
The allogeneic setting showed that the T cells that were expanded at day +5 were 
mainly effector memory T cells. Hence, the number of naïve cells continued to 
decrease in this setting (Figure 11E). In contrast, there was no significant expansion 
observed at day +5 in memory T cells in the syngeneic setting. In summary, donor T 
cells continued their expansion in contrast to the decline in the host T cells (Figure 11). 
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Figure 11: Shows expansion and decline of different cell population:  NK, CD11c, 
CD4 and CD8 cells from allogeneic (connected filled signs) and syngeneic 
(connected open signs) HSCT.  Memory cells from donor (connected filled signs) 
and recipient (connected open sigs).  Donor (filled signs) and recipient (open signs) 
CD11c. 
Figure 12: Serum levels of IL-2, INF-γ and TNF-α at different days after 
allogeneic HSCT. 
Interestingly, the cytokine expression followed the expansion pattern of the cells. 
Interleukin 2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (INF-
γ) in serum had all reached their highest level at day +5 in allogeneic HSCT (Figure 
12).  
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Figure 13: Histology of pancreas, liver, spleen, lung, heart and kidney from day +5 
of syngeneic and allogeneic HSCT.  S: syngeneic A: allogeneic 
 
4.2 STUDY II 
In this study, the same established conditioning regimen was used for syngeneic and 
allogeneic HSCT. The mice tissues were harvested before the conditioning, after the 
conditioning (the same transplantation day), and then at five, seven and twenty one 
days post-HSCT for histology evaluation. The mice of both groups lost weight during 
the conditioning regimen and the weight decrement continued until day +3 and day +7 
in syngeneic and in allogeneic groups, respectively. However, the mice that underwent 
syngeneic transplantation started to gain weight and reached normal levels within three 
weeks, while the weight of mice in the allogeneic group remained low.  The weight loss 
corresponded to the intensity of the GVHD in the allogeneic group, which was not the 
case in the syngeneic setting.  
 
This study showed that the effect of the conditioning regimen was more obvious in 
some tissues compared to others. GVHD intensity also differed between different 
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tissues. Moreover, some tissues showed earlier effect compared to other tissues. In the 
pancreas, no effect of the conditioning regimen was observed and no signs of 
transplantation toxicity were seen in the syngeneic group. In the allogeneic group, the 
pancreas had some abnormalities on days 5 and 7 post HSCT, and this defect remained 
to a lesser extent in some mice and disappeared in other ones. The major pancreatic 
toxicities after allogeneic HSCT were smaller size acini, progressive loss of apical 
secretion granules and apoptotic cell morphology in exocrine and endocrine parts. In 
contrast to the pancreas, the liver was affected by the Bu-Cy conditioning. The 
conditioning resulted in smaller hepatocytes and decrease of cytoplasmic vacuolization. 
The livers from mice treated with allogeneic HSCT had an infiltration of inflammatory 
cells close to the central vein at day +5. On day +7, the livers from mice in the 
allogeneic setting had apoptotic cell forms and granulocytes adhering to the 
endothelium. The livers from the syngeneic HSCT mice had no significant changes. 
The spleen was also affected by the conditioning regimen and by allogeneic HSCT.  
Spleen cellularity decreased dramatically after the conditioning regimen and the 
allogeneic transplanted mice showed sign of change in the architecture. Hypocellularity 
was observed on days +5 and +7, and lymphocyte infiltration was observed within the 
hardly identifiable white pulp. The mice had partially recovered from the spleen 
damage when they were approaching three weeks post HSCT. The spleens from the 
syngeneic group were also hypocellular during the first week post transplantation. 
However, the red pulp showed extensive extramedullar hematopoiesis.  
 
The conditioning regimen did not result in remarkable changes in lung, heart and 
kidney. However, lungs from the allogeneically transplanted mice had inflammatory 
features with adherence of granulocytes in small veins at days +5 and +7. Three weeks 
post transplantation granulocyte infiltration, foamy macrophages and sub-pleural 
fibrotic changes were still observed in some spleens from allogeneically transplanted 
mice. Except for alveolar foam type macrophages, there were no other abnormalities 
detected in the syngeneic group within three weeks post transplantation. Starting day 
+7, some abnormalities in the heart were found with a few apoptotic cells, minimal loss 
of cardiomyocytes and subendocardial accumulation of neutrophils. This observation 
was more pronounced by day +21. The syngeneic HSCT group showed no detectable 
effect within the first three weeks post transplantation. In contrast to all other tissues, 
syngeneic and allogeneic transplantations did not result in detectible effects on the 
kidney. Day +5 is very critical in GVHD development according to this established Bu-
Cy model. Figure 13 shows the histopathology of different tissues in syngeneic and 
allogeneic HSCT on day +5. 
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Figure 14: Force tension relationship. Control active tension (empty circle), Bu-Cy 
active tension (filled circle), control passive tension (empty square) and Bu-Cy 
passive tension (filled square). 
4.3 STUDY III 
4.3.1 Effect of Bu-Cy conditioning on arteries 
General toxicity expressed as a weight loss and vascular toxicity were observed after 
Bu-Cy conditioning regimen. Significant weight loss was observed in the Bu-Cy 
treated animals compared to the control group injected with PBS. However, there was 
no effect from the Bu-Cy treatment on heart weight (both dried and wet) compared to 
the control. The Bu-Cy treated group had lower blood pressure compared to control 
group. The internal circumference (IC) of mesenteric arteries from Bu-Cy treated mice 
was larger compared to the IC obtained from the corresponding segment from the 
controls (Figure A). However, there was no difference between the groups in IC of the 
aorta. The micro vessels from the Bu-Cy treated group were larger and slightly stiffer 
than those of the control group as showed by the extrapolation between tension and IC 
to zero positive tension and the determination of the reference slack IC (ICref) (Figure 
14 B). The relationship between passive tension (PT) and IC/ICref was non-linear with a 
higher stiffness (i.e. the steepness of the relationship between IC/ICref and PT) in the 
Bu-Cy group. The IC/ICref at the optimal length for active force was significantly 
(P<0.001) lower in the Bu-Cy group compared to the control group (Bu-Cy: 1.52 ± 
0.03, n=6 and controls: 1.93 ± 0.06, n=4). The extrapolated curve is illustrated in Figure 
14.  
 
4.3.2 Pharmacological effects 
The aorta from Bu-Cy treated mice had a higher sensitivity to noradrenalin (Figure 15 
B). However, there was no significant difference observed in the noradrenalin reactivity 
of the mesenteric arteries. This result showed that there were no major alterations in the 
contractile adrenoceptor signaling in the mesenteric arteries.  
Acetylcholine, sodium nitroprusside and forskolin relaxant agonist effects were also 
investigated in mesenteric arteries and aorta from the Bu-Cy conditioned mice and the 
control group. Acetylcholine induces endothelium dependent relaxation and sodium 
nitroprusside (SNP) directly activates the relaxant nitric oxide dependent pathways 
A B 
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Figure 16: cAMP and cGMP relaxation pathways 
while forskolin directly activates cyclic adenosine-monophosphate (cAMP) dependent 
relaxation. The mesenteric arteries from Bu-Cy treated mice had a higher sensitivity to 
acetylcholine (Figure 15 A) while there were no significant differences between the Bu-
Cy treated group and the control regarding the response to SNP and forskolin. There 
was no significant difference in the three relaxant agonists in the aorta between 
the two treated groups (Figure 16). In summary, the Bu-Cy treatment enhanced 
endothelium mediated relaxation in microarteries but did not change relaxation 
properties of the aorta. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: A; acetylcholine relaxation steps (mesenteric arteries) and B; noradrenalin 
contraction steps (aorta) from Bu-Cy treated mice (filled symbols) and controls (open 
symbols). 
 
 
4.3.3 Bu-Cy Effect on endothelial cells and nitric oxide  
As mentioned above we 
found higher relaxation 
response to acetylcholine in 
the Bu-Cy treated group 
compared to the control. We 
found that the effect was 
due to the increase in eNOS 
levels as assessed by the 
mRNA and the protein 
expression (Figure 17). 
There were no signs that 
cGMP or cAMP pathways 
were involved. Thus, 
endothelial cells, but not 
smooth muscles, were 
involved in Bu-Cy effect on 
arteries. Figure 16 is a schematic diagram showing the acetylcholine, cGMP and cAMP 
relaxation pathways.  
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Figure 18: Electron microscope picture for control (A) and Bu-Cy treated group 
(B). Arrow (gaps), E (endothelial cells), SMC (smooth muscular cell), * (elastic 
fibers and the bars = 2 µm 
Figure 17: eNOS protein expression in microarteries (M.A.) and aorta of Bu-Cy 
treated (filled bars) and control (open bars) animals. Western blot analyses were 
normalized to β-actin.  
 
 
The electron microscope confirmed the endothelial injury. The endothelial cells were 
detached from the extracellular matrix which disrupted the cell to cell contact (Figure 
18).   
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Table 2: Effect of omega-3 food supplement on mouse weight during Bu-Cy 
conditioning (O3= Omega-3; Std=Standard food; Crn= corn oil; x=versus)  
4.4 STUDY IV 
4.4.1 Animal weight 
The mice in the omega-3 group gained more weight before the start of the conditioning 
regimen compared to the other two groups. The mice in the corn oil group also had a 
higher increase in weight compared to the mice in the standard food group. Bu-Cy 
conditioning regimen resulted in significant weight loss in omega-3, corn oil and 
control groups. However, the weight loss during the conditioning regimen was higher 
in the omega-3 group than in the group of mice that were fed standard food. The corn 
oil also presented similar results, but to a lesser extent compared to the omega-3 group. 
The reduction in weight was greater in the omega-3 group during the standard 
conditioning regimen, but there were no significant differences in weight reduction of 
mice treated with the reduced intensity conditioning regimen and short or long term 
feeding. In contrast, the eight week feeding resulted in a higher reduction of weight in 
the corn oil fed mice during the Bu-Cy standard conditioning.   
 
Food supplement  (D -21) (D -21) to (D -7) % (D -7) to (D 0) % 
Omega-3 20.06 ± 0.51 (n = 20) 9.09 ± 1.17 (n = 20) -18.25 ± 1.29 
Corn oil 20.27 ± 0.59 (n = 20) 7.05 ± 1.39 (n = 20) -16.85 ± 1.01 
Standard  20.53 ± 0.49 (n = 20) 4.59 ± 1.12 (n = 20) -12.40 ± 1.18  
Ttest (O3 x Std) P =0.52 P =0.01 P =0.002 
Ttest (Crn x Std) P =0.74 P =0.18 P =0.01 
4.4.2 Cellularity  
4.4.2.1 BM and spleen cellularity 
The cellularity of bone marrow did not differ significantly between the three groups in 
the short or long term feeding when the mice received standard Bu-Cy conditioning. 
 
However, the group fed omega-3 had significantly lower BM cellularity when the mice 
had received reduced intensity conditioning with long term feeding compared to the 
standard food and to corn oil. The spleen cellularity was lower in both PUFA fed 
groups compared to the control in standard Bu-Cy conditioning. However, spleen 
cellularity from the omega-3 and corn oil fed groups was lower in the long term feeding 
and the standard intensity conditioning compared to the standard food group (Figure 
19).  
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Figure 19: BM and spleen cellularity. A, B: short term feeding and RIC regimen; 
C, D: long term feeding and RIC; E, F: short term feeding and standard Bu-Cy 
conditioning and G, H: long term feeding and standard Bu-Cy conditioning 
Figure 20: CD11b+ cells from standard Bu-Cy conditioning. A, B; short  
term feeding; C, D: long term feeding. * represents significant findings 
 
4.4.2.2 Subpopulation cellularity  
CD11b+ myeloid cell population was significantly lower in the group of omega-3 fed 
mice compared to the other groups. The result was significant in short and long term 
feeding. It was also significant in reduced intensity conditioning. However, there was 
no significant difference in CD11b+ cells between the three supplements without Bu-
Cy conditioning regimen (Figure 20). CD11c+CD86+ dendritic cells were also 
significantly reduced in mice fed omega-3 and given Bu-Cy conditioning. The effect of 
omega-3 on CD11c+CD86+ cells was significant in long and short term feeding 
(Figure 21).  
There was no significant difference in memory and naïve T cells between the three 
groups in the short term feeding with the standard conditioning regimen; however, 
omega-3 significantly reduced both memory and naïve CD8+ T cells in long term 
feeding.  
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Figure 21: CD11cCD86+ cells from spleen after RIC (A, B), standard Bu-Cy 
conditioning (C, D). A, C; short term feeding; B, D: long term feeding.  
* represents significant findings 
Figure 22: CD4+CD25+FoxP3+ T cells from spleen after RIC (A, B), standard 
Bu-Cy conditioning (C, D). A, C; short term feeding and B, D: long term feeding. 
* represents significant findings 
 
 
4.4.3 Regulatory T cells and MLC 
CD4+CD25+FoxP3+ regulatory T cells were significantly lower in the group of 
omega-3 fed mice which either received the Bu-Cy conditioning regimen (Figure 22) or 
in the group that was given the food without conditioning. To test if the effect was only 
on cell number or if it also affected function, we assessed this effect using mixed 
lymphocyte culture. The result of this experiment showed a slight effect of omega-3 on 
the Treg function. The ratio of 1:1 responder cells to Treg cells showed no obvious 
difference on Treg suppression between the three groups. However, as the Treg cells 
decreased, the difference between the three groups increased to the lower suppression 
of Treg cells in the omega-3 group. 
 
   
4.4.4 Busulfan effect on CFU-GM 
There was no significant difference in busulfan toxicity on CFU-GM between the 
omega-3, corn oil and standard food groups.  
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Figure 23: Survival analysis for mice fed omega-3, corn oil or standard food for three 
weeks before HSCT. The mice received standard Bu-Cy conditioning. Administration 
of the three food supplements continued after HSCT.  
4.4.5 GVHD and animal survival 
The mice fed omega-3 had a lower survival rate compared to the mice fed corn oil or 
standard food (Figure 23). Moreover, the mice in the omega-3 group had severe 
diarrhea. The mice in this group presented signs of GVHD as described in the method 
section. The corn oil group also had lower survival compared to the standard food. 
However, the mice in corn oil group did not show obvious sign of GVHD. BM and 
spleen chimerism from the omega-3 showed higher engraftment compared to the corn 
oil and the control group. The mice from the corn oil group which died had the lowest 
cell engraftment among the three groups.    
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5 DISCUSSION  
HSCT is the treatment of choice for many diseases. Despite continuous development of 
this procedure, HSCT is still limited by life threatening complications. Conditioning 
regimen is an important part of HSCT. A majority of the experimental studies are based 
on irradiation conditioning regimen, despite the fact that about 50% of the patients 
undergoing HSCT receive chemotherapy as a conditioning regimen. The studies 
discussed in this thesis were based on busulfan and cyclophosphamide conditioning. 
The rationale was the common use of this regimen in HSCT setting. As well as being 
used as a conditioning regimen for HSCT, these two drugs are also used for the 
treatment of some diseases; cyclophosphamide, for example, is also used in cancer 
treatment. Thus, studying their action and toxicity in HSCT will also benefit their use in 
other applications. Our studies focused on conditioning related toxicities and factors 
that may affect HSCT outcome. 
In the first study we investigated the early pathophysiological events in GVHD. The 
Bu-Cy dose used in this study was myeloablative and resulted in over 95% elimination 
of BM cells. The conditioning is considered immunosuppressive with its reduction of 
over 60% of total splenic cells indicating that T cells might be more resistant to the 
chemotherapy. T cells were reduced by 30 %, while B, NK and DC cells decreased by 
more than 70%. Cytokine production was not high at day 0 (day of transplantation) but 
reached maximum levels at day +5 after HSCT. At this point, a high T cell proliferation 
could also be seen. This might to some extent distinguish between radiotherapy and 
chemotherapy conditioning; high levels of cytokines have been reported after 
irradiation conditioning [100, 307]. Since the levels of inflammatory cytokines were 
low on the day of transplantation compared to those reported in irradiation conditioning 
and high on day +5 in Bu-Cy conditioning, we can conclude that the cytokines are less 
involved in the development of GVHD when Bu-Cy conditioning has been used 
compared with irradiation. It might also suggest that Bu-Cy conditioning has delayed 
tissue injury compared to the irradiation conditioning.   
 
As we reported in this study, the increase of NK and DC cells soon after transplantation 
showed the importance of these cells in the early stages of the inflammatory process, 
which could influence the establishment of the GVHD. These two populations reached 
their peak of expansion at day +3, which was also the start of T cell proliferation. The 
expansion of T cells reached its first maximum peak at day +5. Most of these T cells 
were of donor origin and the majority of them were CD8+ cells. This process was seen 
at the same time as two other observations were made. The first of these was the 
highest expression level of IL-2, TNF-α and INF-γ inflammatory cytokines. The second 
observation was the clinical symptoms of GVHD. GVHD is initiated by injury from the 
conditioning regimen. The second signal is from the expansion of the innate immune 
system followed by the adaptive immune system. Thus, the increase of antigen 
presenting cells (APC) soon after HSCT is an important signal for the production and 
proliferation of T cells as well as the increase of inflammatory cytokines. Although 
DCs on day +1 were mainly from the host, the high level at day +3 was of donor origin. 
Interestingly, the ratio of naïve to effector memory T cells was decreased, which means 
that by the time, the effector memory T cells were increasing. This indicated the 
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existence of GVHD. The allogeneic setting induced the inflammatory response that was 
absent in the syngeneic setting.        
   
In the second study we investigated the histopathological changes in the allogeneic 
HSCT process at different time points from the beginning of the conditioning regimen 
to 21 days after stem cell transplantation. This study showed that the damage caused by 
the Bu-Cy conditioning regimen and GVHD are affecting different tissues by different 
severity grade. The study has showed that some tissues are sensitive to the Bu-Cy 
conditioning regimen, whereas others may be less sensitive to the treatment. GVHD 
has also been shown to have selective mediation to different tissues. This indicates that 
unaffected tissues have a protective or a fast repairing mechanism. As reported, the 
liver is one of the target organs [308-309]. We also observed tissue damage starting 
from the conditioning regimen and being enhanced by the allogeneic HSCT. A similar 
pattern was observed in the spleen where some chemotherapy toxicities (later enhanced 
by the allogeneic transplantation) were detected. We did not detect morphological 
changes in the pancreas and the heart after the conditioning regimen, but both organs 
exhibited some degree of damage during GVHD development. However, the damage in 
these organs was lesser than that found in the liver and the spleen. In contrast to the 
above four tissues, there was no morphological change detected in the kidney after Bu-
Cy conditioning regimen and allogeneic HSCT.  
It is possible that the Bu-Cy conditioning has no histopathological toxicity on the heart, 
pancreas and kidney or that the damage was minor and hence could not be detected by 
morphological changes. Moreover, most of the Bu-Cy toxicity reported might be 
caused by cylophosphamide, which might explain the obvious damage to the liver as 
Cy is metabolized mainly there [310-312]. However, this could not explain why the 
kidney was not damaged by this regimen – after all, it filters the excessive metabolites, 
although majority of them are inactive [313]. Although the mice were of inbred strain, 
there were great inter-individual differences after chemotherapy and HSCT. It is 
important to understand the pathophysiology of GVHD, and it is also of importance to 
understand the mechanism of its progression. The highest amount of damage found 
after HSCT developed mainly in the first week as shown previously [314].  
 
Long-term cardiovascular toxicity after HSCT has been reported [286, 315]; however, 
the early effects of conditioning and HSCT on the arterial system [286] have not been 
yet elucidated. Hence, the third study focused specifically on Bu-Cy toxicity on the 
arterial system.  
We selected the mesenteric arteries and the aorta to study the effect of Bu-Cy 
conditioning on the vascular system according to their impact in cardiovascular 
diseases. Micro-vessels (also called resistance vessels) have a small diameter and direct 
the blood to different organs. Defective micro-vessels may lead to organ dysfunction. 
Mesenteric arteries are micro-vessels located in the mesentery which contribute to 
peripheral resistance. The aorta is the large artery which passes the blood to major 
organs. Effects on aorta elasticity also have an impact on heart function [316]. 
Although the initial internal circumference (IC) of aortas from Bu-Cy treated mice was 
not significantly different from the control, the stretched aortas had a smaller IC 
compared to the control. This means that aortas from Bu-Cy conditioned mice had 
lower elasticity, which might have an impact on the other observation in the mesenteric 
arteries: the initial IC was larger in the Bu-Cy group compared to the control. This 
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could be the result of a compensation mechanism. The mesenteric arteries from the Bu-
Cy treated mice were more sensitive to acetylcholine compared to the control. The 
larger IC and the increased relaxation with acetylcholine lowered the blood pressure. 
This result also supported the increased heart rate that was found in the Bu-Cy treated 
group. The increased heart rate was possibly a compensatory mechanism for the lower 
systemic blood pressure.        
The mesenteric arteries from the Bu-Cy group had a higher production of endothelial 
nitric oxide (eNOS), which might explain the mechanism behind the increased 
sensitivity to acetylcholine dependent relaxation. The cAMP and cGMP pathways were 
not affected by the Bu-Cy conditioning, excluding smooth muscle defect as the source.  
Mesenteric arteries from Bu-Cy treated mice showed a higher level of the mRNA and 
the eNOS gene as well as protein expression from both genes respectively. An 
increased level of nitric oxide [317] and a larger internal circumference might also 
decrease the blood pressure, which we found in another set of experiments after Bu-Cy 
conditioning. Although nitric oxide deficiency is associated with some diseases [318-
319], a high level of nitric oxide could also exert toxicity [320]. The electron 
microscope examination showed damaged endothelial layers in the mesenteric arteries 
and a decrease in cell to cell contact. The defects in endothelial cell to cell contact 
affect different features of vascular homeostasis, which in turn affects different 
processes such as the permeability of the vessels and the infiltration of leukocytes to the 
inflamed tissues [321]. The damage to the endothelial cell layers might also affect 
organ perfusion (and thus long term function) to some degree. The Bu-Cy conditioning 
had less effect on the physiological properties of the aorta compared to its effect on the 
mesenteric arteries. However, the higher sensitivity of the aorta to noradrenalin may 
also reflect damages to the endothelium [322]. The results of this study indicate an 
early change in the vascular system that may influence later development of 
cardiovascular disease after HSCT. 
The fourth project investigated the effect of omega-3 on the Bu-Cy conditioning 
regimen and on GVHD development after allogeneic HSCT. Omega-3 effects were 
reported in different types of diseases, especially inflammatory and autoimmune 
diseases [245]. Omega-3 has been reported to modify the effect of several drugs used in 
cancer chemotherapy and the treatment of other diseases. Omega-3 has been reported to 
enhance the treatment of breast cancer [323] and to decrease tissue damage after 
irradiation [324]. From these studies and others, it seems that omega-3 enhances the 
efficacy of chemotherapy and also has beneficial effects on life quality in general [325]. 
Although the beneficial effects of omega-3 on cancer and chemotherapy have not been 
fully elucidated, they are some reported pathways. Omega-3 may increase the efficacy 
of chemotherapy without damaging the normal cells by reducing the oxidative stress 
caused by the therapeutic agents and by changing the fat composition of the cells. DHA 
and EPA, two major omega-3 derivatives, are reported to inhibit eicosanoid synthesis 
from the AA [326] and reduce the COX-2 expression [327]. The competitor properties 
of EPA and DHA to AA reduce the inflammatory condition through a decrease in the 
inflammatory mediators LTB4 and PGE2. The EPA and DHA may work as substitutes 
for cytochrome P450 (CYP) AA dependent metabolites and hence reduce toxicity 
caused by eicosanoids [328].       
Despite extensive studies of omega-3 and its role in disease pathophysiology, 
prevention and treatment, their mechanism of action is still not well understood. The 
HSCT procedure is complex, involving donor and recipient immune systems, 
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immunosuppressive drugs to prevent and treat rejection and GVHD, drugs for 
treatment of other complications and frequently limited food intake. This complexity 
makes it hard to evaluate the effect of food supplements on chemotherapy and HSCT in 
clinical settings. Thus, we used the established mouse model which, to a certain extent, 
limits the number of variables compared to human transplantation. The food was 
supplemented for three weeks and two months in order to evaluate the benefits of short 
and long term feeding, respectively. Since the use of reduced intensity conditioning is 
common, we also studied the effects of omega-3 in combination with RIC. This might 
also reveal the effects of omega-3 which had been hidden by myeloablative 
conditioning. However, standard dose Bu-Cy conditioning was used with all 
transplantation experiments.  
CD4+CD25+FoxP3+ regulatory T cells were significantly lower before the 
conditioning regimen in all groups and after the conditioning in the omega-3 fed group. 
It was reported that Cy selectively depletes Treg cells [329-330] and that Cy 
immunosuppressive properties were enhanced by EPA [239]. Hence, omega-3 is seen 
to suppress the Treg cells independent of conditioning regimen. Moreover, in the 
conditioning there was a dual effect resulting from the direct effect of omega-3 and the 
Cy enhancement effect. We then evaluated if omega-3 decreased the number of Treg 
cells and if it also diminished their suppressive function. The results showed that there 
was minor effect when the ratio of Treg to responder cells was even (i.e.1: 1). This 
effect was more obvious in the decreased number of Treg cells in omega-3 fed mice 
compared to those fed corn oil and standard food respectively. We conclude that 
omega-3 significantly deteriorates the number of Treg cells, but has only a slight effect 
on their suppressive properties. Treg cells are known to suppress cytotoxic T cell 
activity [331].  
Omega-3 supplementation for three weeks, including the period of Bu-Cy conditioning, 
augments GVHD. The effect stemmed from the enhancement of the myeloablative 
effects of Bu-Cy conditioning through a decrease in the number of CD11b+ cells. The 
effects of omega-3 also stemmed from the reduction of activated dendritic cells, which 
are reported to play an important role in the initiation of GVHD [314]. Thus, omega-3 
enhanced Bu-Cy conditioning and resulted in a more rapid death of the mice in the 
omega-3 fed group compared to the corn oil and standard food groups. The corn oil 
group also showed a higher death rate after HSCT as compared to the mice in the 
standard food group. However, the mice in the omega-3 group started to have diarrhea 
and display standard signs of GVHD early on, while the mice in the corn oil group 
showed a sign of anemia. The result was also confirmed by the full cell engraftment of 
the bone marrow and spleen in the omega-3 group. In contrast, the spleens from the 
corn oil group had a lower amount of donor cells. We also conducted another 
experiment where the donors were fed omega-3 before transplantation. The overall 
survival increased in the omega-3 recipient group, and was close to that in the standard 
food group. The mice in the corn oil group also had a slight improvement in survival. 
One of the transplanted groups that received HSCT from omega-3 fed donors and 
continued with omega-3 after the transplantation showed survival similar to that of the 
mice in the standard food group. Moreover, the mice in this group were more active 
compared to other groups.  The results from this study showed that omega-3 augments 
GVHD through the enhancement of Bu-Cy conditioning and by suppressing the 
regulatory T cell numbers and functions. Moreover, omega-3 may help to suppress 
inflammatory reactions in recipients that survive the acute phase of GVHD. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 Our stem cell transplantation mouse model following busulfan-
cyclophosphamide (Bu-Cy) conditioning is a reliable model for studying 
several factors that are involved in the development of graft versus host 
disease after chemotherapy. It is also a useful model for evaluating different 
agents in the treatment of GVHD. All studies in this thesis utilized this model.  
 Naïve T cells undergo early allo-activation by host/donor APCs in the 
secondary lymphoid organs to produce effector/memory T cells that initiate 
tissue damage in GVHD.  
 Decreased spleen cellularity and diminished glycogen content in the liver 
were observed after conditioning regimen. No morphological changes were 
observed in kidney in either HSCT setting.  
 Histopathological changes such as vasculitis, inflammation and apoptotic cell 
forms in liver, spleen, pancreas, lungs and heart were observed in allogeneic 
transplanted mice, however, only hypocellular spleen and extramedullar 
hematopoiesis were detected in syngeneic transplanted animals.  
 Short term consequences of Bu-Cy treatment divergently affect large and 
small arteries of the cardiovascular system.  
 The increased noradrenaline reactivity of large elastic arteries was not 
associated with increased blood pressure. Instead, Bu-Cy treatment lowered 
blood pressure via augmented microvascular endothelial dependent relaxation, 
increased expression of vascular eNOS and remodeling toward a larger lumen.  
 The changes in microarterial properties can be associated with direct effects of 
the compounds on vascular wall or possibly indirectly induced via altered 
translational activity associated with the reduced hematocrit and shear stress. 
 Omega-3 as food supplement enhances graft versus host disease (GVHD) 
through a suppression of the regulatory T cells in mice receiving Bu-Cy 
conditioning regimen. 
 Omega-3 intake caused an enhancement of Bu-Cy conditioning regimen 
myeloablation and toxicity. 
 Corn oil as food supplement decreased the cell engraftment which led to BMT 
rejection or death from anemia. 
 
1. Further evaluation of the vascular system after HSCT is warranted, including 
the effects of aGVHD and cGVHD. Effects of the Bu-Cy conditioning need to 
be studied in vessel segments from different organs. 
2. More studies are needed to evaluate the effect of long term intake of omega-3 
in HSCT setting. This is an important issue for patients undergoing HSCT. 
3. General studies to evaluate the effects of omega-3 on the vascular system in 
combination with different conditioning regimens are warranted.  
4. Moreover, the effects of diets in general in conjunction with HSCT might play 
an important role in the clinical outcome and have to be investigated.  
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9 ABSTRAKT 
Hematopoietisk stamcellstransplantation (HSCT) är en botande behandling för ett 
flertal maligna och icke-maligna sjukdomar. Tyvärr begränsas dess användbarhet av 
transplantationsrelaterade komplikationer och dödlighet. Komplikationerna kan orsakas 
av olika faktorer inklusive förbehandlingsrelaterad toxicitet och allogeneicitet. Trots att 
50 % av transplantationspatienterna förbehandlas med cellgifter, baseras de flesta 
transplantationsmodeller på förbehandling med strålning. I försöken i denna avhandling 
använde vi en musmodell som innebär HSCT efter förbehandling med busulfan-
cyklofosfamid (Bu-Cy) för att undersöka de mekanismer och faktorer som kan påverka 
graft versus host disease (GVHD) och/eller behandlingsrelaterad toxicitet, vilket kan 
påverka transplantationsresultatet.    
Studie I: Denna studie formgavs för att undersöka tidig celldynamik under 
utvecklandet av GVHD efter allogeneisk HSCT. Vi fann en tidig expansion och 
aktivering av dendritiska celler (DCs) som nådde sin höjdpunkt på dag +3 post HSCT. 
T-cellsexpansionen startade senare och nådde sin höjdpunkt på dag +5 post HSCT. 
Majoriteten av dessa celler var CD8+ celler från donatorn. De inflammatoriska 
cytokinerna (IL-2, INF-γ och TNF-α) nådde också maximala nivåer på dag +5 efter 
transplantationen. Resultaten visade på den viktiga roll som donatorns DCs spelar i 
utvecklingen av GVHD.    
Studie II: Vi studerade tidiga histopatologiska förändringar i organen vid olika 
tidpunkter efter förbehandling samt utvecklingen av GVHD fram till dag +21 efter 
transplantation. Studien visade att levern och mjälten var de organ som påverkades 
mest, medan inga morfologiska effekter syntes i pankreas, hjärtat, lungorna eller 
njurarna efter förbehandlingen. Histopatologiska förändringar såsom vaskulit, 
inflammation och apoptotiska cellformer i levern, mjälten, pankreas, lungorna och 
hjärtat observerades under utvecklingen av GVHD; hypocellulär mjälte och 
extramedullär hematopoies syntes däremot bara hos syngeneiskt transplanterade djur. 
Inga morfologiska förändringar kunde observeras i njurarna vid endera sortens HSCT. 
Dessa resultat kan vara till hjälp i våra försök att förstå de mekanismer som ligger till 
grund för utvecklingen av GVHD.     
Studie III: Vi undersökte den toxiska effekt som förbehandling med Bu-Cy kan ha på 
artärerna. Vi fann att förbehandlingen förstärkte acetylkolinavslappning i de 
mesenteriska artärerna genom ett ökat uttryck av kväveoxid i endotheliet. I motsats till 
detta var aortans känslighet för acetylkolin ungefär densamma i den grupp som 
förbehandlats med Bu-Cy och hos kontrollgruppen. Aortor från cytostatikabehandlade 
djur visade däremot en högre känslighet för noradrenalin. De djur som behandlats med 
Bu-Cy hade lägre blodtryck, lägre hematokrit och större skador på endotheliet jämfört 
med kontrollgruppen. Dessa resultat kan vara användbara för att utveckla profylaktisk 
behandling för kardiovaskulära komplikationer. 
Studie IV: Vi studerade effekten av omega-3 på förbehandling med Bu-Cy och på 
resultatet av allogeneisk HSCT med fokus på GVHD. Vi använde majsolja och 
standardfoder till kontrollgrupperna. De möss som fick kost som berikats med omega-3 
hade den lägsta överlevnadsfrekvensen och visade tidiga tecken på GVHD. Omega-3 
förstärkte effekten hos förbehandlingen genom att förhöja dess myeloablativa 
egenskaper, förminska uttrycket av CD4+CD25+FoxP3+ T celler och begränsa dessas 
funktion. En lägre förekomst av GVHD och en högre avstötningsfrekvens kunde ses 
hos kontrollgruppen som åt majsolja. Den högre mortalitetsfrekvensen hos den grupp 
som åt omega-3 kan förklaras av en förhöjd myeloablativ effekt och ökad förekomst av 
grav akut GVHD. 
 
Sammantaget kan dessa studier förbättra vår kunskap om GVHD och 
förbehandlingsrelaterad toxicitet. Behandlingsstrategier kan förbättras, vilket också kan 
leda till bättre resultat av HSCT. 
